<full-text-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/article/dtd" xmlns:bk="http://www.elsevier.com/xml/bk/dtd" xmlns:cals="http://www.elsevier.com/xml/common/cals/dtd" xmlns:ce="http://www.elsevier.com/xml/common/dtd" xmlns:ja="http://www.elsevier.com/xml/ja/dtd" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:sa="http://www.elsevier.com/xml/common/struct-aff/dtd" xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd" xmlns:tb="http://www.elsevier.com/xml/common/table/dtd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>https://api.elsevier.com/content/article/pii/S1359644602022900</prism:url><dc:identifier>doi:10.1016/S1359-6446(02)02290-0</dc:identifier><eid>1-s2.0-S1359644602022900</eid><prism:doi>10.1016/S1359-6446(02)02290-0</prism:doi><pii>S1359-6446(02)02290-0</pii><dc:title>Structural biology in drug design: selective protein kinase inhibitors </dc:title><prism:publicationName>Drug Discovery Today</prism:publicationname><prism:aggregationType>Journal</prism:aggregationtype><pubType>rev</pubtype><prism:issn>13596446</prism:issn><prism:volume>7</prism:volume><prism:issueIdentifier>11</prism:issueidentifier><prism:startingPage>601</prism:startingpage><prism:endingPage>611</prism:endingpage><prism:pageRange>601-611</prism:pagerange><prism:number>11</prism:number><dc:format>text/xml</dc:format><prism:coverDate>2002-05-06</prism:coverdate><prism:coverDisplayDate>6 May 2002</prism:coverdisplaydate><prism:copyright>Copyright © 2002 Elsevier Science Ltd. All rights reserved.</prism:copyright><prism:publisher>Elsevier Science Ltd.</prism:publisher><dc:creator>Scapin, Giovanna</dc:creator><dc:description>
                  Protein kinases have a fundamental role in signal transduction pathways, and aberrant kinase activity has been observed in many diseases. In recent years, kinase inhibition has become a major area for therapeutic intervention and a variety of kinase inhibitor pharmacophores has been described. This review illustrates some of the efforts and results in the field of structure-based design of protein kinase inhibitors. The methods and results discussed here illustrate the power of structure-based design in lead discovery, for example via virtual screening and in guiding the optimization of the pharmacological properties of these molecules.
               </dc:description><openaccess>0</openaccess><openaccessArticle>false</openaccessarticle><openaccessType/></openaccesstype><openArchiveArticle>false</openarchivearticle><openaccessSponsorName/></openaccesssponsorname><openaccessSponsorType/></openaccesssponsortype><openaccessUserLicense/></openaccessuserlicense><dcterms:subject>structure-based inhibitor design</dcterms:subject><dcterms:subject>protein kinases</dcterms:subject><dcterms:subject>selectivity</dcterms:subject><dcterms:subject>catalytic domain</dcterms:subject><dcterms:subject>regulatory domain</dcterms:subject><link href="https://api.elsevier.com/content/article/pii/S1359644602022900" rel="self"/></link><link href="https://www.sciencedirect.com/science/article/pii/S1359644602022900" rel="scidir"/></link></coredata><objects><object ref="gr9" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1332" height="948" size="91076">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644602022900-gr9_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr8" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2053" height="1187" size="148143">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644602022900-gr8_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr7" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="963" height="1652" size="95086">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644602022900-gr7_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr6" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1332" height="1411" size="238007">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644602022900-gr6_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1330" height="689" size="58394">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644602022900-gr5_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1333" height="1604" size="144143">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644602022900-gr4_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2057" height="1496" size="183265">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644602022900-gr3_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="963" height="713" size="97504">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644602022900-gr2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1107" height="1578" size="193868">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644602022900-gr1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr9" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="501" height="357" size="29752">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644602022900-gr9.jpg?httpAccept=%2A%2F%2A</object><object ref="gr8" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="773" height="447" size="45535">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644602022900-gr8.jpg?httpAccept=%2A%2F%2A</object><object ref="gr7" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="362" height="621" size="30186">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644602022900-gr7.jpg?httpAccept=%2A%2F%2A</object><object ref="gr6" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="501" height="531" size="71592">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644602022900-gr6.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="500" height="259" size="19066">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644602022900-gr5.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="502" height="604" size="46364">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644602022900-gr4.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="774" height="563" size="55562">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644602022900-gr3.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="362" height="268" size="29524">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644602022900-gr2.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="416" height="593" size="66574">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644602022900-gr1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr9" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="156" size="3866">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644602022900-gr9.sml?httpAccept=%2A%2F%2A</object><object ref="gr8" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="127" size="3176">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644602022900-gr8.sml?httpAccept=%2A%2F%2A</object><object ref="gr7" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="95" height="163" size="1521">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644602022900-gr7.sml?httpAccept=%2A%2F%2A</object><object ref="gr6" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="155" height="164" size="9585">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644602022900-gr6.sml?httpAccept=%2A%2F%2A</object><object ref="gr5" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="113" size="2037">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644602022900-gr5.sml?httpAccept=%2A%2F%2A</object><object ref="gr4" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="136" height="164" size="3117">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644602022900-gr4.sml?httpAccept=%2A%2F%2A</object><object ref="gr3" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="159" size="3023">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644602022900-gr3.sml?httpAccept=%2A%2F%2A</object><object ref="gr2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="162" size="18021">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644602022900-gr2.sml?httpAccept=%2A%2F%2A</object><object ref="gr1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="115" height="164" size="5958">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644602022900-gr1.sml?httpAccept=%2A%2F%2A</object></objects><scopus-id>0036591874</scopus-id><scopus-eid>2-s2.0-0036591874</scopus-eid><pubmed-id>12047871</pubmed-id><link href="https://api.elsevier.com/content/abstract/scopus_id/0036591874" rel="abstract"/></link><originalText><xocs:doc xsi:schemaLocation="http://www.elsevier.com/xml/xocs/dtd http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd"><xocs:meta xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <xocs:content-family>serial</xocs:content-family>
      <xocs:content-type>JL</xocs:content-type>
      <xocs:cid>271275</xocs:cid>
      <xocs:ssids>
         <xocs:ssid type="alllist">291210</xocs:ssid>
         <xocs:ssid type="subj">291727</xocs:ssid>
         <xocs:ssid type="subj">291850</xocs:ssid>
         <xocs:ssid type="subj">291928</xocs:ssid>
         <xocs:ssid type="content">31</xocs:ssid>
      </xocs:ssids>
      <xocs:srctitle>Drug Discovery Today</xocs:srctitle>
      <xocs:normalized-srctitle>DRUGDISCOVERYTODAY</xocs:normalized-srctitle>
      <xocs:orig-load-date yyyymmdd="20020528">2002-05-28</xocs:orig-load-date>
      <xocs:available-online-date yyyymmdd="20020528">2002-05-28</xocs:available-online-date>
      <xocs:ew-transaction-id>2014-11-24T08:52:45</xocs:ew-transaction-id>
      <xocs:eid>1-s2.0-S1359644602022900</xocs:eid>
      <xocs:pii-formatted>S1359-6446(02)02290-0</xocs:pii-formatted>
      <xocs:pii-unformatted>S1359644602022900</xocs:pii-unformatted>
      <xocs:doi>10.1016/S1359-6446(02)02290-0</xocs:doi>
      <xocs:item-stage>S300</xocs:item-stage>
      <xocs:item-version-number>S300.2</xocs:item-version-number>
      <xocs:item-weight>FULL-TEXT</xocs:item-weight>
      <xocs:hub-eid>1-s2.0-S1359644600X00682</xocs:hub-eid>
      <xocs:timestamp yyyymmdd="20150515">2015-05-15T05:43:12.598483-04:00</xocs:timestamp>
      <xocs:dco>0</xocs:dco>
      <xocs:tomb>0</xocs:tomb>
      <xocs:date-search-begin>20020506</xocs:date-search-begin>
      <xocs:year-nav>2002</xocs:year-nav>
      <xocs:indexeddate epoch="1022544000">2002-05-28T00:00:00Z</xocs:indexeddate>
      <xocs:articleinfo>articleinfo articletitlenorm authfirstinitialnorm authfirstsurnamenorm cid cids contenttype copyright crossmark dateloaded dateloadedtxt datesearch datesort dateupdated dco docsubtype doctype doi eid ewtransactionid hubeid indexeddate issfirst issn issnnorm issuelist itemstage itemtransactionid itemweight openaccess openarchive pg pgfirst pglast pii piinorm pubdatestart pubdatetxt pubyr sortorder srctitle srctitlenorm srctype ssids alllist content subj subheadings tomb volfirst volissue volumelist webpdf webpdfpagecount yearnav figure body acknowledge affil articletitle auth authfirstini authfull authkeywords authlast doctopic otherkwds primabst pubtype ref</xocs:articleinfo>
      <xocs:issns>
         <xocs:issn-primary-formatted>1359-6446</xocs:issn-primary-formatted>
         <xocs:issn-primary-unformatted>13596446</xocs:issn-primary-unformatted>
      </xocs:issns>
      <xocs:crossmark is-crossmark="0">false</xocs:crossmark>
      <xocs:vol-first>7</xocs:vol-first>
      <xocs:volume-list>
         <xocs:volume>7</xocs:volume>
      </xocs:volume-list>
      <xocs:iss-first>11</xocs:iss-first>
      <xocs:issue-list>
         <xocs:issue>11</xocs:issue>
      </xocs:issue-list>
      <xocs:vol-iss-suppl-text>Volume 7, Issue 11</xocs:vol-iss-suppl-text>
      <xocs:sort-order>12</xocs:sort-order>
      <xocs:first-fp>601</xocs:first-fp>
      <xocs:last-lp>611</xocs:last-lp>
      <xocs:pages>
         <xocs:first-page>601</xocs:first-page>
         <xocs:last-page>611</xocs:last-page>
      </xocs:pages>
      <xocs:cover-date-orig>
         <xocs:start-date>20020506</xocs:start-date>
      </xocs:cover-date-orig>
      <xocs:cover-date-text>6 May 2002</xocs:cover-date-text>
      <xocs:cover-date-start>2002-05-06</xocs:cover-date-start>
      <xocs:cover-date-year>2002</xocs:cover-date-year>
      <xocs:document-type>converted-article</xocs:document-type>
      <xocs:document-subtype>rev</xocs:document-subtype>
      <xocs:copyright-line>Copyright © 2002 Elsevier Science Ltd. All rights reserved.</xocs:copyright-line>
      <xocs:normalized-article-title>STRUCTURALBIOLOGYINDRUGDESIGNSELECTIVEPROTEINKINASEINHIBITORS</xocs:normalized-article-title>
      <xocs:normalized-first-auth-surname>SCAPIN</xocs:normalized-first-auth-surname>
      <xocs:normalized-first-auth-initial>G</xocs:normalized-first-auth-initial>
      <xocs:item-toc>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Structure of protein kinases</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>Overall structure</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>ATP-binding site</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Kinase inhibition</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>ATP-competitive inhibitors</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>Cyclin-dependent kinases</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>ErbB/EGFR kinase</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>Janus kinase 3</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>Abl kinase</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Inhibition of intra-macromolecular interactions</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>SH3 domains</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>SH2 domains</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>C1B domain of PKC</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Conclusions</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:acknowledgment">
            <xocs:item-toc-section-title>Acknowledgements</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:bibliography">
            <xocs:item-toc-section-title>References</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
      </xocs:item-toc>
      <xocs:references>
         <xocs:ref-info refid="BIB1">
            <xocs:ref-normalized-surname>HUNTER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1995</xocs:ref-pub-year>
            <xocs:ref-first-fp>225</xocs:ref-first-fp>
            <xocs:ref-last-lp>236</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="BIB2">
            <xocs:ref-normalized-surname>JOHNSON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2001</xocs:ref-pub-year>
            <xocs:ref-first-fp>2209</xocs:ref-first-fp>
            <xocs:ref-last-lp>2242</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="BIB3">
            <xocs:ref-normalized-surname>NEEL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1997</xocs:ref-pub-year>
            <xocs:ref-first-fp>193</xocs:ref-first-fp>
            <xocs:ref-last-lp>204</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="BIB4">
            <xocs:ref-normalized-surname>KENNELLY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2001</xocs:ref-pub-year>
            <xocs:ref-first-fp>2291</xocs:ref-first-fp>
            <xocs:ref-last-lp>2312</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="BIB5">
            <xocs:ref-normalized-surname>JACKSON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2001</xocs:ref-pub-year>
            <xocs:ref-first-fp>2313</xocs:ref-first-fp>
            <xocs:ref-last-lp>2340</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="BIB6">
            <xocs:ref-normalized-surname>SAITO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2001</xocs:ref-pub-year>
            <xocs:ref-first-fp>2497</xocs:ref-first-fp>
            <xocs:ref-last-lp>2510</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="BIB7">
            <xocs:ref-normalized-surname>SCHLESSINGER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1992</xocs:ref-pub-year>
            <xocs:ref-first-fp>383</xocs:ref-first-fp>
            <xocs:ref-last-lp>391</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="BIB8">
            <xocs:ref-normalized-surname>HUBBARD</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2000</xocs:ref-pub-year>
            <xocs:ref-first-fp>373</xocs:ref-first-fp>
            <xocs:ref-last-lp>398</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="BIB9">
            <xocs:ref-normalized-surname>CHEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2001</xocs:ref-pub-year>
            <xocs:ref-first-fp>2449</xocs:ref-first-fp>
            <xocs:ref-last-lp>2476</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Z</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="BIB10">
            <xocs:ref-normalized-surname>KNIGHTON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1991</xocs:ref-pub-year>
            <xocs:ref-first-fp>407</xocs:ref-first-fp>
            <xocs:ref-last-lp>414</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="BIB11">
            <xocs:ref-normalized-surname>HANKS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1995</xocs:ref-pub-year>
            <xocs:ref-first-fp>576</xocs:ref-first-fp>
            <xocs:ref-last-lp>596</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="BIB12">
            <xocs:ref-normalized-surname>JOHNSON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1996</xocs:ref-pub-year>
            <xocs:ref-first-fp>149</xocs:ref-first-fp>
            <xocs:ref-last-lp>158</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="BIB13">
            <xocs:ref-normalized-surname>ADAMS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2001</xocs:ref-pub-year>
            <xocs:ref-first-fp>2271</xocs:ref-first-fp>
            <xocs:ref-last-lp>2290</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="BIB14">
            <xocs:ref-normalized-surname>ROBERTSON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2000</xocs:ref-pub-year>
            <xocs:ref-first-fp>265</xocs:ref-first-fp>
            <xocs:ref-last-lp>271</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="BIB15">
            <xocs:ref-normalized-surname>MULLERLADNER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1996</xocs:ref-pub-year>
            <xocs:ref-first-fp>210</xocs:ref-first-fp>
            <xocs:ref-last-lp>220</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>U</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="BIB16">
            <xocs:ref-normalized-surname>TAYLOR</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1997</xocs:ref-pub-year>
            <xocs:ref-first-fp>219</xocs:ref-first-fp>
            <xocs:ref-last-lp>226</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="BIB17">
            <xocs:ref-normalized-surname>BRIDGES</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2001</xocs:ref-pub-year>
            <xocs:ref-first-fp>2541</xocs:ref-first-fp>
            <xocs:ref-last-lp>2572</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="BIB18">
            <xocs:ref-normalized-surname>TOLEDO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1999</xocs:ref-pub-year>
            <xocs:ref-first-fp>775</xocs:ref-first-fp>
            <xocs:ref-last-lp>805</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="BIB19">
            <xocs:ref-normalized-surname>TRAXLER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1997</xocs:ref-pub-year>
            <xocs:ref-first-fp>571</xocs:ref-first-fp>
            <xocs:ref-last-lp>588</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="BIB20">
            <xocs:ref-normalized-surname>TRAXLER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1998</xocs:ref-pub-year>
            <xocs:ref-first-fp>1599</xocs:ref-first-fp>
            <xocs:ref-last-lp>1625</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="BIB21">
            <xocs:ref-normalized-surname>LAWRENCE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1998</xocs:ref-pub-year>
            <xocs:ref-first-fp>81</xocs:ref-first-fp>
            <xocs:ref-last-lp>114</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="BIB22">
            <xocs:ref-normalized-surname>DUMAS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2001</xocs:ref-pub-year>
            <xocs:ref-first-fp>405</xocs:ref-first-fp>
            <xocs:ref-last-lp>429</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="BIB23">
            <xocs:ref-normalized-surname>BROADBRIDGE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2000</xocs:ref-pub-year>
            <xocs:ref-first-fp>365</xocs:ref-first-fp>
            <xocs:ref-last-lp>386</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="BIB24">
            <xocs:ref-normalized-surname>VU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2000</xocs:ref-pub-year>
            <xocs:ref-first-fp>1081</xocs:ref-first-fp>
            <xocs:ref-last-lp>1100</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="BIB25">
            <xocs:ref-normalized-surname>CODY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2000</xocs:ref-pub-year>
            <xocs:ref-first-fp>59</xocs:ref-first-fp>
            <xocs:ref-last-lp>98</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="BIB26">
            <xocs:ref-normalized-surname>YEH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2001</xocs:ref-pub-year>
            <xocs:ref-first-fp>12235</xocs:ref-first-fp>
            <xocs:ref-last-lp>12240</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="BIB27">
            <xocs:ref-normalized-surname>BLUM</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2000</xocs:ref-pub-year>
            <xocs:ref-first-fp>15705</xocs:ref-first-fp>
            <xocs:ref-last-lp>15712</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="BIB28">
            <xocs:ref-normalized-surname>PARANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2001</xocs:ref-pub-year>
            <xocs:ref-first-fp>37</xocs:ref-first-fp>
            <xocs:ref-last-lp>41</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="BIB29">
            <xocs:ref-normalized-surname>HARPER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2001</xocs:ref-pub-year>
            <xocs:ref-first-fp>957</xocs:ref-first-fp>
            <xocs:ref-last-lp>973</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="BIB30">
            <xocs:ref-normalized-surname>ADAMS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2001</xocs:ref-pub-year>
            <xocs:ref-first-fp>1</xocs:ref-first-fp>
            <xocs:ref-last-lp>60</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="BIB31">
            <xocs:ref-normalized-surname>SAUSVILLE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2000</xocs:ref-pub-year>
            <xocs:ref-first-fp>1</xocs:ref-first-fp>
            <xocs:ref-last-lp>3</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="BIB32">
            <xocs:ref-normalized-surname>WANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1998</xocs:ref-pub-year>
            <xocs:ref-first-fp>1117</xocs:ref-first-fp>
            <xocs:ref-last-lp>1128</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Z</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="BIB33">
            <xocs:ref-normalized-surname>SCHINDLER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1999</xocs:ref-pub-year>
            <xocs:ref-first-fp>639</xocs:ref-first-fp>
            <xocs:ref-last-lp>648</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="BIB34">
            <xocs:ref-normalized-surname>ZHU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1999</xocs:ref-pub-year>
            <xocs:ref-first-fp>651</xocs:ref-first-fp>
            <xocs:ref-last-lp>661</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>X</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="BIB35">
            <xocs:ref-normalized-surname>LIU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1999</xocs:ref-pub-year>
            <xocs:ref-first-fp>671</xocs:ref-first-fp>
            <xocs:ref-last-lp>678</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="BIB36">
            <xocs:ref-normalized-surname>BROOKS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1999</xocs:ref-pub-year>
            <xocs:ref-first-fp>455</xocs:ref-first-fp>
            <xocs:ref-last-lp>463</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="BIB37">
            <xocs:ref-normalized-surname>WEBSTER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1998</xocs:ref-pub-year>
            <xocs:ref-first-fp>940</xocs:ref-first-fp>
            <xocs:ref-last-lp>943</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="BIB38">
            <xocs:ref-normalized-surname>SENDEROWICZ</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1998</xocs:ref-pub-year>
            <xocs:ref-first-fp>2899</xocs:ref-first-fp>
            <xocs:ref-last-lp>2986</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="BIB39">
            <xocs:ref-normalized-surname>SCHULZEGAHMEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1995</xocs:ref-pub-year>
            <xocs:ref-first-fp>378</xocs:ref-first-fp>
            <xocs:ref-last-lp>391</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>U</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="BIB40">
            <xocs:ref-normalized-surname>DEAZEVEDO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1996</xocs:ref-pub-year>
            <xocs:ref-first-fp>2735</xocs:ref-first-fp>
            <xocs:ref-last-lp>2740</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="BIB41">
            <xocs:ref-normalized-surname>FURET</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2000</xocs:ref-pub-year>
            <xocs:ref-first-fp>403</xocs:ref-first-fp>
            <xocs:ref-last-lp>409</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="BIB42">
            <xocs:ref-normalized-surname>FURET</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2001</xocs:ref-pub-year>
            <xocs:ref-first-fp>489</xocs:ref-first-fp>
            <xocs:ref-last-lp>495</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="BIB43">
            <xocs:ref-normalized-surname>GUSSIO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2000</xocs:ref-pub-year>
            <xocs:ref-first-fp>53</xocs:ref-first-fp>
            <xocs:ref-last-lp>66</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="BIB44">
            <xocs:ref-normalized-surname>GRAY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1998</xocs:ref-pub-year>
            <xocs:ref-first-fp>533</xocs:ref-first-fp>
            <xocs:ref-last-lp>538</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="BIB45">
            <xocs:ref-normalized-surname>KIM</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1998</xocs:ref-pub-year>
            <xocs:ref-first-fp>555</xocs:ref-first-fp>
            <xocs:ref-last-lp>565</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="BIB46">
            <xocs:ref-normalized-surname>IKUTA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2001</xocs:ref-pub-year>
            <xocs:ref-first-fp>27548</xocs:ref-first-fp>
            <xocs:ref-last-lp>27554</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="BIB47"/></xocs:ref-info>
         <xocs:ref-info refid="BIB48">
            <xocs:ref-normalized-surname>FURET</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1995</xocs:ref-pub-year>
            <xocs:ref-first-fp>465</xocs:ref-first-fp>
            <xocs:ref-last-lp>471</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="BIB49">
            <xocs:ref-normalized-surname>TRAXLER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1999</xocs:ref-pub-year>
            <xocs:ref-first-fp>195</xocs:ref-first-fp>
            <xocs:ref-last-lp>206</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="BIB50">
            <xocs:ref-normalized-surname>GHOSH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1999</xocs:ref-pub-year>
            <xocs:ref-first-fp>403</xocs:ref-first-fp>
            <xocs:ref-last-lp>410</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="BIB51">
            <xocs:ref-normalized-surname>MAHAJAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1999</xocs:ref-pub-year>
            <xocs:ref-first-fp>9587</xocs:ref-first-fp>
            <xocs:ref-last-lp>9599</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="BIB52">
            <xocs:ref-normalized-surname>SINGH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1997</xocs:ref-pub-year>
            <xocs:ref-first-fp>1130</xocs:ref-first-fp>
            <xocs:ref-last-lp>1135</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="BIB53">
            <xocs:ref-normalized-surname>IHLE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1995</xocs:ref-pub-year>
            <xocs:ref-first-fp>1</xocs:ref-first-fp>
            <xocs:ref-last-lp>35</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="BIB54">
            <xocs:ref-normalized-surname>WITTHUHN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1999</xocs:ref-pub-year>
            <xocs:ref-first-fp>289</xocs:ref-first-fp>
            <xocs:ref-last-lp>297</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="BIB55">
            <xocs:ref-normalized-surname>SUDBECK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1999</xocs:ref-pub-year>
            <xocs:ref-first-fp>1569</xocs:ref-first-fp>
            <xocs:ref-last-lp>1582</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="BIB56">
            <xocs:ref-normalized-surname>SCHINDLER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2000</xocs:ref-pub-year>
            <xocs:ref-first-fp>1938</xocs:ref-first-fp>
            <xocs:ref-last-lp>1942</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="BIB57">
            <xocs:ref-normalized-surname>KIKKAWA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1989</xocs:ref-pub-year>
            <xocs:ref-first-fp>31</xocs:ref-first-fp>
            <xocs:ref-last-lp>44</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>U</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="BIB58">
            <xocs:ref-normalized-surname>KURIYAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1997</xocs:ref-pub-year>
            <xocs:ref-first-fp>259</xocs:ref-first-fp>
            <xocs:ref-last-lp>288</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="BIB59">
            <xocs:ref-normalized-surname>BURKE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2001</xocs:ref-pub-year>
            <xocs:ref-first-fp>32</xocs:ref-first-fp>
            <xocs:ref-last-lp>44</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="BIB60">
            <xocs:ref-normalized-surname>QIAO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2001</xocs:ref-pub-year>
            <xocs:ref-first-fp>955</xocs:ref-first-fp>
            <xocs:ref-last-lp>959</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="BIB61">
            <xocs:ref-normalized-surname>DALGARNO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1997</xocs:ref-pub-year>
            <xocs:ref-first-fp>383</xocs:ref-first-fp>
            <xocs:ref-last-lp>400</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="BIB62">
            <xocs:ref-normalized-surname>COMBS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1996</xocs:ref-pub-year>
            <xocs:ref-first-fp>287</xocs:ref-first-fp>
            <xocs:ref-last-lp>288</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="BIB63">
            <xocs:ref-normalized-surname>NGUYEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1998</xocs:ref-pub-year>
            <xocs:ref-first-fp>2088</xocs:ref-first-fp>
            <xocs:ref-last-lp>2092</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="BIB64">
            <xocs:ref-normalized-surname>SAWYER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1998</xocs:ref-pub-year>
            <xocs:ref-first-fp>243</xocs:ref-first-fp>
            <xocs:ref-last-lp>261</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="BIB65">
            <xocs:ref-normalized-surname>LUNNEY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1997</xocs:ref-pub-year>
            <xocs:ref-first-fp>12471</xocs:ref-first-fp>
            <xocs:ref-last-lp>12476</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="BIB66">
            <xocs:ref-normalized-surname>BUCHANAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1999</xocs:ref-pub-year>
            <xocs:ref-first-fp>2353</xocs:ref-first-fp>
            <xocs:ref-last-lp>2358</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="BIB67">
            <xocs:ref-normalized-surname>SHAKESPEARE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2000</xocs:ref-pub-year>
            <xocs:ref-first-fp>3815</xocs:ref-first-fp>
            <xocs:ref-last-lp>3819</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="BIB68">
            <xocs:ref-normalized-surname>SHAKESPEARE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2000</xocs:ref-pub-year>
            <xocs:ref-first-fp>9373</xocs:ref-first-fp>
            <xocs:ref-last-lp>9378</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="BIB69">
            <xocs:ref-normalized-surname>FURET</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1998</xocs:ref-pub-year>
            <xocs:ref-first-fp>3442</xocs:ref-first-fp>
            <xocs:ref-last-lp>3449</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="BIB70">
            <xocs:ref-normalized-surname>FURET</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1999</xocs:ref-pub-year>
            <xocs:ref-first-fp>2358</xocs:ref-first-fp>
            <xocs:ref-last-lp>2363</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="BIB71">
            <xocs:ref-normalized-surname>OBRIAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1998</xocs:ref-pub-year>
            <xocs:ref-first-fp>305</xocs:ref-first-fp>
            <xocs:ref-last-lp>309</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="BIB72">
            <xocs:ref-normalized-surname>ZHANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1995</xocs:ref-pub-year>
            <xocs:ref-first-fp>917</xocs:ref-first-fp>
            <xocs:ref-last-lp>924</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
      </xocs:references>
      <xocs:refkeys>
         <xocs:refkey3>SCAPINX2002X601</xocs:refkey3>
         <xocs:refkey4lp>SCAPINX2002X601X611</xocs:refkey4lp>
         <xocs:refkey4ai>SCAPINX2002X601XG</xocs:refkey4ai>
         <xocs:refkey5>SCAPINX2002X601X611XG</xocs:refkey5>
      </xocs:refkeys>
      <xocs:open-access>
         <xocs:oa-article-status is-open-access="0" is-open-archive="0"/></xocs:oa-article-status>
      </xocs:open-access>
      <xocs:attachment-metadata-doc>
         <xocs:attachment-set-type>item</xocs:attachment-set-type>
         <xocs:pii-formatted>S1359-6446(02)02290-0</xocs:pii-formatted>
         <xocs:pii-unformatted>S1359644602022900</xocs:pii-unformatted>
         <xocs:eid>1-s2.0-S1359644602022900</xocs:eid>
         <xocs:doi>10.1016/S1359-6446(02)02290-0</xocs:doi>
         <xocs:cid>271275</xocs:cid>
         <xocs:timestamp>2014-11-24T03:56:50.78534-05:00</xocs:timestamp>
         <xocs:cover-date-start>2002-05-06</xocs:cover-date-start>
         <xocs:attachments>
            <xocs:web-pdf>
               <xocs:attachment-eid>1-s2.0-S1359644602022900-main.pdf</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644602022900/MAIN/application/pdf/3965a2416afa33b211b117fc4a17b8e8/main.pdf</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644602022900/MAIN/application/pdf/3965a2416afa33b211b117fc4a17b8e8/main.pdf</xocs:ucs-locator>
               <xocs:filename>main.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:pdf-optimized>true</xocs:pdf-optimized>
               <xocs:filesize>245707</xocs:filesize>
               <xocs:web-pdf-purpose>MAIN</xocs:web-pdf-purpose>
               <xocs:web-pdf-page-count>11</xocs:web-pdf-page-count>
               <xocs:web-pdf-images>
                  <xocs:web-pdf-image>
                     <xocs:attachment-eid>1-s2.0-S1359644602022900-main_1.png</xocs:attachment-eid>
                     <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644602022900/PREVIEW/image/png/de7cfcbbf47d4757a0d8cc0869c910b5/main_1.png</xocs:ucs-locator>
                     <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644602022900/PREVIEW/image/png/de7cfcbbf47d4757a0d8cc0869c910b5/main_1.png</xocs:ucs-locator>
                     <xocs:filename>main_1.png</xocs:filename>
                     <xocs:extension>png</xocs:extension>
                     <xocs:filesize>75449</xocs:filesize>
                     <xocs:pixel-height>849</xocs:pixel-height>
                     <xocs:pixel-width>656</xocs:pixel-width>
                     <xocs:attachment-type>IMAGE-WEB-PDF</xocs:attachment-type>
                     <xocs:pdf-page-num>1</xocs:pdf-page-num>
                  </xocs:web-pdf-image>
               </xocs:web-pdf-images>
            </xocs:web-pdf>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644602022900-gr9_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644602022900/gr9/HIGHRES/image/jpeg/a20304f633a1ea0949ec6cf1f4d808f8/gr9_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644602022900/gr9/HIGHRES/image/jpeg/a20304f633a1ea0949ec6cf1f4d808f8/gr9_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr9</xocs:file-basename>
               <xocs:filename>gr9_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>91076</xocs:filesize>
               <xocs:pixel-height>948</xocs:pixel-height>
               <xocs:pixel-width>1332</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644602022900-gr8_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644602022900/gr8/HIGHRES/image/jpeg/bc03d1d377a7b5cc4a73edfafdc6eac9/gr8_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644602022900/gr8/HIGHRES/image/jpeg/bc03d1d377a7b5cc4a73edfafdc6eac9/gr8_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr8</xocs:file-basename>
               <xocs:filename>gr8_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>148143</xocs:filesize>
               <xocs:pixel-height>1187</xocs:pixel-height>
               <xocs:pixel-width>2053</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644602022900-gr7_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644602022900/gr7/HIGHRES/image/jpeg/566f81ecccb6a4b791f484b80a9da486/gr7_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644602022900/gr7/HIGHRES/image/jpeg/566f81ecccb6a4b791f484b80a9da486/gr7_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>95086</xocs:filesize>
               <xocs:pixel-height>1652</xocs:pixel-height>
               <xocs:pixel-width>963</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644602022900-gr6_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644602022900/gr6/HIGHRES/image/jpeg/c61e5bfa3a8a03c35d40ae2a05fe0c0f/gr6_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644602022900/gr6/HIGHRES/image/jpeg/c61e5bfa3a8a03c35d40ae2a05fe0c0f/gr6_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>238007</xocs:filesize>
               <xocs:pixel-height>1411</xocs:pixel-height>
               <xocs:pixel-width>1332</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644602022900-gr5_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644602022900/gr5/HIGHRES/image/jpeg/73cf22ee7c386d76031fc19c4a777583/gr5_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644602022900/gr5/HIGHRES/image/jpeg/73cf22ee7c386d76031fc19c4a777583/gr5_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>58394</xocs:filesize>
               <xocs:pixel-height>689</xocs:pixel-height>
               <xocs:pixel-width>1330</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644602022900-gr4_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644602022900/gr4/HIGHRES/image/jpeg/f998ada596ea59850dc12c3e0934a938/gr4_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644602022900/gr4/HIGHRES/image/jpeg/f998ada596ea59850dc12c3e0934a938/gr4_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>144143</xocs:filesize>
               <xocs:pixel-height>1604</xocs:pixel-height>
               <xocs:pixel-width>1333</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644602022900-gr3_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644602022900/gr3/HIGHRES/image/jpeg/ebfd3a20b92140e25a4e0b2151b5550a/gr3_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644602022900/gr3/HIGHRES/image/jpeg/ebfd3a20b92140e25a4e0b2151b5550a/gr3_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>183265</xocs:filesize>
               <xocs:pixel-height>1496</xocs:pixel-height>
               <xocs:pixel-width>2057</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644602022900-gr2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644602022900/gr2/HIGHRES/image/jpeg/531bf31013c1fc4e10659451785742f6/gr2_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644602022900/gr2/HIGHRES/image/jpeg/531bf31013c1fc4e10659451785742f6/gr2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>97504</xocs:filesize>
               <xocs:pixel-height>713</xocs:pixel-height>
               <xocs:pixel-width>963</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644602022900-gr1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644602022900/gr1/HIGHRES/image/jpeg/a24657dea55bc1a4e1cb2599e85a1024/gr1_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644602022900/gr1/HIGHRES/image/jpeg/a24657dea55bc1a4e1cb2599e85a1024/gr1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>193868</xocs:filesize>
               <xocs:pixel-height>1578</xocs:pixel-height>
               <xocs:pixel-width>1107</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644602022900-gr9.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644602022900/gr9/DOWNSAMPLED/image/jpeg/24178260f058425b41cdb95bed2207de/gr9.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644602022900/gr9/DOWNSAMPLED/image/jpeg/24178260f058425b41cdb95bed2207de/gr9.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr9</xocs:file-basename>
               <xocs:filename>gr9.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>29752</xocs:filesize>
               <xocs:pixel-height>357</xocs:pixel-height>
               <xocs:pixel-width>501</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644602022900-gr8.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644602022900/gr8/DOWNSAMPLED/image/jpeg/dc88ddf7bae772ba4de63f108d6de786/gr8.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644602022900/gr8/DOWNSAMPLED/image/jpeg/dc88ddf7bae772ba4de63f108d6de786/gr8.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr8</xocs:file-basename>
               <xocs:filename>gr8.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>45535</xocs:filesize>
               <xocs:pixel-height>447</xocs:pixel-height>
               <xocs:pixel-width>773</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644602022900-gr7.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644602022900/gr7/DOWNSAMPLED/image/jpeg/9d758c69e410f1f3d7672146576484df/gr7.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644602022900/gr7/DOWNSAMPLED/image/jpeg/9d758c69e410f1f3d7672146576484df/gr7.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>30186</xocs:filesize>
               <xocs:pixel-height>621</xocs:pixel-height>
               <xocs:pixel-width>362</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644602022900-gr6.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644602022900/gr6/DOWNSAMPLED/image/jpeg/dba18a34aa10e2b24fb9b5f4abb055f6/gr6.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644602022900/gr6/DOWNSAMPLED/image/jpeg/dba18a34aa10e2b24fb9b5f4abb055f6/gr6.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>71592</xocs:filesize>
               <xocs:pixel-height>531</xocs:pixel-height>
               <xocs:pixel-width>501</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644602022900-gr5.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644602022900/gr5/DOWNSAMPLED/image/jpeg/988a9228d501ae847b849f943348eca9/gr5.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644602022900/gr5/DOWNSAMPLED/image/jpeg/988a9228d501ae847b849f943348eca9/gr5.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>19066</xocs:filesize>
               <xocs:pixel-height>259</xocs:pixel-height>
               <xocs:pixel-width>500</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644602022900-gr4.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644602022900/gr4/DOWNSAMPLED/image/jpeg/ef22dd98eab09b2e584b7ac159539ce1/gr4.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644602022900/gr4/DOWNSAMPLED/image/jpeg/ef22dd98eab09b2e584b7ac159539ce1/gr4.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>46364</xocs:filesize>
               <xocs:pixel-height>604</xocs:pixel-height>
               <xocs:pixel-width>502</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644602022900-gr3.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644602022900/gr3/DOWNSAMPLED/image/jpeg/230da3f59cb101ff6eeb5f58a65154c8/gr3.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644602022900/gr3/DOWNSAMPLED/image/jpeg/230da3f59cb101ff6eeb5f58a65154c8/gr3.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>55562</xocs:filesize>
               <xocs:pixel-height>563</xocs:pixel-height>
               <xocs:pixel-width>774</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644602022900-gr2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644602022900/gr2/DOWNSAMPLED/image/jpeg/82a9669ff387aa3752107d01e543e59d/gr2.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644602022900/gr2/DOWNSAMPLED/image/jpeg/82a9669ff387aa3752107d01e543e59d/gr2.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>29524</xocs:filesize>
               <xocs:pixel-height>268</xocs:pixel-height>
               <xocs:pixel-width>362</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644602022900-gr1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644602022900/gr1/DOWNSAMPLED/image/jpeg/82b239b2ed03b3523e48ea47d00af4f6/gr1.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644602022900/gr1/DOWNSAMPLED/image/jpeg/82b239b2ed03b3523e48ea47d00af4f6/gr1.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>66574</xocs:filesize>
               <xocs:pixel-height>593</xocs:pixel-height>
               <xocs:pixel-width>416</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644602022900-gr9.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644602022900/gr9/THUMBNAIL/image/gif/5de8da895bd7faeec212363d8476e862/gr9.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644602022900/gr9/THUMBNAIL/image/gif/5de8da895bd7faeec212363d8476e862/gr9.sml</xocs:ucs-locator>
               <xocs:file-basename>gr9</xocs:file-basename>
               <xocs:filename>gr9.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3866</xocs:filesize>
               <xocs:pixel-height>156</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644602022900-gr8.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644602022900/gr8/THUMBNAIL/image/gif/cdf4633fcca0d09c76298f2e910bc681/gr8.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644602022900/gr8/THUMBNAIL/image/gif/cdf4633fcca0d09c76298f2e910bc681/gr8.sml</xocs:ucs-locator>
               <xocs:file-basename>gr8</xocs:file-basename>
               <xocs:filename>gr8.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3176</xocs:filesize>
               <xocs:pixel-height>127</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644602022900-gr7.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644602022900/gr7/THUMBNAIL/image/gif/e4f42354f591b129f8446f13752e42a9/gr7.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644602022900/gr7/THUMBNAIL/image/gif/e4f42354f591b129f8446f13752e42a9/gr7.sml</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>1521</xocs:filesize>
               <xocs:pixel-height>163</xocs:pixel-height>
               <xocs:pixel-width>95</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644602022900-gr6.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644602022900/gr6/THUMBNAIL/image/gif/2548893c06e6e34b2be16f3e7c7d8fe0/gr6.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644602022900/gr6/THUMBNAIL/image/gif/2548893c06e6e34b2be16f3e7c7d8fe0/gr6.sml</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>9585</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>155</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644602022900-gr5.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644602022900/gr5/THUMBNAIL/image/gif/f411b0b1f71f665341dc3ed1b46ca344/gr5.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644602022900/gr5/THUMBNAIL/image/gif/f411b0b1f71f665341dc3ed1b46ca344/gr5.sml</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2037</xocs:filesize>
               <xocs:pixel-height>113</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644602022900-gr4.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644602022900/gr4/THUMBNAIL/image/gif/79ad5c8cb46bb5de218c20393fd66173/gr4.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644602022900/gr4/THUMBNAIL/image/gif/79ad5c8cb46bb5de218c20393fd66173/gr4.sml</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3117</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>136</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644602022900-gr3.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644602022900/gr3/THUMBNAIL/image/gif/cfac86d5ab8607ea92643c669c597ade/gr3.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644602022900/gr3/THUMBNAIL/image/gif/cfac86d5ab8607ea92643c669c597ade/gr3.sml</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3023</xocs:filesize>
               <xocs:pixel-height>159</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644602022900-gr2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644602022900/gr2/THUMBNAIL/image/gif/80b95256e44a6a7b143db2287eb8a7ea/gr2.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644602022900/gr2/THUMBNAIL/image/gif/80b95256e44a6a7b143db2287eb8a7ea/gr2.sml</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>18021</xocs:filesize>
               <xocs:pixel-height>162</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644602022900-gr1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644602022900/gr1/THUMBNAIL/image/gif/b705ee969cfd172cc6dd5e600499936e/gr1.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644602022900/gr1/THUMBNAIL/image/gif/b705ee969cfd172cc6dd5e600499936e/gr1.sml</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>5958</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>115</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
         </xocs:attachments>
      </xocs:attachment-metadata-doc>
   </xocs:meta><xocs:serial-item xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <converted-article xmlns="http://www.elsevier.com/xml/ja/dtd" version="4.5.2" docsubtype="rev" xml:lang="en">
         <item-info>
            <jid>DRUDIS</jid>
            <aid>00002290</aid>
            <ce:pii>S1359-6446(02)02290-0</ce:pii>
            <ce:doi>10.1016/S1359-6446(02)02290-0</ce:doi>
            <ce:copyright type="full-transfer" year="2002">Elsevier Science Ltd</ce:copyright>
            <ce:doctopics>
               <ce:doctopic>
                  <ce:text>Research focus</ce:text>
               </ce:doctopic>
            </ce:doctopics>
         </item-info>
         <ce:floats>
            <ce:figure id="FIG1">
               <ce:label>Fig. 1</ce:label>
               <ce:caption>
                  <ce:simple-para view="all">Ribbon diagram showing the catalytic domain of extracellular-signal-regulated kinase (ERK2) (Protein Data Bank code ERK1). The 11 subdomains that comprise the catalytic domain are shown in different colors.</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr1"/></ce:link>
            </ce:figure>
            <ce:figure id="FIG2">
               <ce:label>Fig. 2</ce:label>
               <ce:caption>
                  <ce:simple-para view="all">The ATP-binding cleft in human lymphocyte specific kinase (LCK; Protein Data Bank code 3LCK). The regions composing the binding site are: (1) the adenine binding region, yellow; (2) the sugar pocket, aqua; (3) the phosphate binding region, orange; (4) the hydrophobic region 1, behind the adenine ring, blue; and (5) the hydrophobic region 2, a cleft or a tunnel adjacent to the ribose pocket, magenta.</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr2"/></ce:link>
            </ce:figure>
            <ce:figure id="FIG3">
               <ce:label>Fig. 3</ce:label>
               <ce:caption>
                  <ce:simple-para view="all">Small-molecule inhibitors of cyclin-dependent protein kinases (CDKs). Analysis of the binding mode of <ce:bold>i</ce:bold> lead to the design and synthesis of the more potent compound <ce:bold>iii</ce:bold>, in which the interactions with the hydrophobic pocket (Ala31, Val64, Phe80 and Ala145) and the side chains of Asp86 and Gln132 are optimized. Comparison of the binding mode of <ce:bold>i</ce:bold> and <ce:bold>ii</ce:bold> led to the design of a scaffold that facilitates the identification of new, potent inhibitors of CDK1, exemplified by <ce:bold>iv</ce:bold>, which retains the potency of <ce:bold>ii</ce:bold> and the selectivity profile of <ce:bold>i</ce:bold>. Molecular modeling and mechanical calculations were used to modify the paullone scaffold <ce:bold>v</ce:bold>: this approach resulted in the discovery of a 9-nitropaullone with nanomolar potency. Abbreviations: PKA, ATP-dependent protein kinase; PKCα, protein kinase Cα; EGFR, epidermal growth factor receptor.</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr3"/></ce:link>
            </ce:figure>
            <ce:figure id="FIG4">
               <ce:label>Fig. 4</ce:label>
               <ce:caption>
                  <ce:simple-para view="all">Small-molecule inhibitors of epidermal growth factor receptor (EGFR) and Bruton's tyrosine kinase (BTK) kinases. Compound <ce:bold>vii</ce:bold> and <ce:bold>viii</ce:bold>, although derived from the same parent compound (<ce:bold>vi</ce:bold>), are remarkably selective for their target. The K<ce:inf loc="post">i</ce:inf> for EGFR inhibitors 4-anilinoquinazolines (<ce:bold>ix</ce:bold>, starting compound, and <ce:bold>x</ce:bold>, best compound identified) were estimated by modeling studies; the IC<ce:inf loc="post">50</ce:inf> values were measured by transfilter cell-invasion assays <ce:cross-ref refid="BIB50">[50]</ce:cross-ref>. These compounds were shown to inhibit the proliferation and <ce:italic>in vitro</ce:italic> invasiveness of EGFR-positive human breast-cancer cells. Abbreviation: LFM, leflunomide.</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr4"/></ce:link>
            </ce:figure>
            <ce:figure id="FIG5">
               <ce:label>Fig. 5</ce:label>
               <ce:caption>
                  <ce:simple-para view="all">STI571 is a very selective Abl kinase inhibitor. This class of compounds has been approved by the FDA for treatment of chronic myelogenous leukemia (CML). Abbreviations: EGFR, epidermal growth factor receptor; PKCα, protein kinase Cα; PDGFR, platelet-derived growth factor receptor.</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr5"/></ce:link>
            </ce:figure>
            <ce:figure id="FIG6">
               <ce:label>Fig. 6</ce:label>
               <ce:caption>
                  <ce:simple-para view="all">
                     <ce:bold>(a)</ce:bold> Ribbon diagram of the c-CRK SH3 domain in complex with the C3G peptide [Pro-Pro-Pro-Ala-Leu-Pro-Pro-Lys-Lys-Arg; Protein Data Bank (PDB) code 1CKA]. The surface of the protein is shown in grey. The proline-rich peptide adopts a left-handed type II polyproline helix configuration, in which one residue in every three faces the SH3 domain. At the surface of the SH3 domain these residues interact with a recognition platform consisting of highly conserved aromatic residues (Trp, Tyr, Phe) and a proline. Other ionic interactions have an important role in the recognition process, for example, those with the acidic cluster represented by the two glutamates in the figure. <ce:bold>(b)</ce:bold> Ribbon diagram of human p56-LCK in complex with an 11-residue phosphotyrosyl peptide (PDB code 1LCJ). <ce:bold>(c)</ce:bold> Binding surface for the p56-LCK SH2 domain: for clarity, only the phosphotyrosine (in position pY) and the residue in position pY+3 of the bound peptide are shown.</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr6"/></ce:link>
            </ce:figure>
            <ce:figure id="FIG7">
               <ce:label>Fig. 7</ce:label>
               <ce:caption>
                  <ce:simple-para view="all">Small molecule, non-peptidic inhibitors of the Src homolgy 2 (SH2) domain with <ce:italic>in vivo</ce:italic> inhibition of osteoclast-mediated bone resorption. The high affinity is achieved by positioning of the seven-member ring over the side chain of Tyr181, which forms the hydrophobic region that separates the pTyr and the pY+3 pockets.</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr7"/></ce:link>
            </ce:figure>
            <ce:figure id="FIG8">
               <ce:label>Fig. 8</ce:label>
               <ce:caption>
                  <ce:simple-para view="all">Progress in the design of small molecule, non-peptidic inhibitors of the Grb–SH2 domain. Analysis of the structure of Grb2–SH2 in complex with the phosphopeptide <ce:bold>xvi</ce:bold> revealed the presence of a large hydrophobic region near the C-terminal end of the peptide formed by the side chains of Leu βD′1, Phe βE3 and the hydrocarbon part of the side chain of Lys βD6. This feature was exploited in the design of <ce:bold>xvii</ce:bold>, in which the 3-naphtalen-1-yl-propyl group interacts with this area <ce:cross-ref refid="BIB69">[69]</ce:cross-ref>. The presence of three hydrogen bond interactions made by the ligand asparagine with the main chain atoms of Lys βD6 and Leu βE4, and its position and conformation (I+2 of a type I β-turn), were used to design queries for a database search that resulted in the replacement of the asparagine with a β-amino acid mimetic (<ce:bold>xviii</ce:bold>, <ce:cross-ref refid="BIB70">[70]</ce:cross-ref>)</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr8"/></ce:link>
            </ce:figure>
            <ce:figure id="FIG9">
               <ce:label>Fig. 9</ce:label>
               <ce:caption>
                  <ce:simple-para view="all">Small-molecule protein kinase C (PKC) activators that could be used in the treatment of prostrate cancer. Based on the X-ray structure of PKCδC1b in complex with phorbol 13-acetate <ce:cross-ref refid="BIB72">[72]</ce:cross-ref> and the structure of the potent activator <ce:bold>xix</ce:bold>, with the aid of molecular modeling, a new class of PKC modulators – exemplified by <ce:bold>xx</ce:bold> – was designed <ce:cross-ref refid="BIB60">[60]</ce:cross-ref>. These pyrrolidone analogues maintain the hydrogen-bonding network that is crucial for interaction with PKC.</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr9"/></ce:link>
            </ce:figure>
         </ce:floats>
         <head>
            <ce:dochead>
               <ce:textfn>Review</ce:textfn>
            </ce:dochead>
            <ce:title>Structural biology in drug design: selective protein kinase inhibitors</ce:title>
            <ce:author-group>
               <ce:author>
                  <ce:given-name>Giovanna</ce:given-name>
                  <ce:surname>Scapin</ce:surname>
                  
               </ce:author>
               <ce:affiliation>
                  <ce:textfn>Merck Research Laboratories, PO Box 2000, RY50 105, Rahway, NJ 07065, USA tel: +1 732 594 8429, fax: +1 732 594 5042</ce:textfn>
               </ce:affiliation>
            </ce:author-group>
            <ce:abstract class="author"><ce:abstract-sec>
                  <ce:simple-para view="all">Protein kinases have a fundamental role in signal transduction pathways, and aberrant kinase activity has been observed in many diseases. In recent years, kinase inhibition has become a major area for therapeutic intervention and a variety of kinase inhibitor pharmacophores has been described. This review illustrates some of the efforts and results in the field of structure-based design of protein kinase inhibitors. The methods and results discussed here illustrate the power of structure-based design in lead discovery, for example via virtual screening and in guiding the optimization of the pharmacological properties of these molecules.</ce:simple-para>
               </ce:abstract-sec></ce:abstract>
            <ce:keywords class="keyword">
               <ce:section-title>Keywords</ce:section-title>
               <ce:keyword>
                  <ce:text>structure-based inhibitor design</ce:text>
               </ce:keyword>
               <ce:keyword>
                  <ce:text>protein kinases</ce:text>
               </ce:keyword>
               <ce:keyword>
                  <ce:text>selectivity</ce:text>
               </ce:keyword>
               <ce:keyword>
                  <ce:text>catalytic domain</ce:text>
               </ce:keyword>
               <ce:keyword>
                  <ce:text>regulatory domain</ce:text>
               </ce:keyword>
            </ce:keywords>
            <ce:keywords class="idt">
               <ce:section-title>Keywords</ce:section-title>
               <ce:keyword>
                  <ce:text>Drug Discovery</ce:text>
               </ce:keyword>
               <ce:keyword>
                  <ce:text>Biochemistry</ce:text>
               </ce:keyword>
               <ce:keyword>
                  <ce:text>Bioinformatics</ce:text>
               </ce:keyword>
               <ce:keyword>
                  <ce:text>Biotechnology</ce:text>
               </ce:keyword>
            </ce:keywords>
         </head>
         <body>
            <ce:sections>
               <ce:para view="all">The phosphorylation of proteins, triggered in response to extracellular signals, represents a universal mechanism for the cellular control of many different processes, including metabolic pathways, cell growth and differentiation, membrane transport, and apoptosis <ce:cross-refs refid="BIB1 BIB2">[1,2]</ce:cross-refs>. The reverse reaction of dephosphorylation is catalyzed by specific protein phosphatases <ce:cross-refs refid="BIB3 BIB4 BIB5">[3–5]</ce:cross-refs>. Phosphorylation of protein targets is catalyzed by a large family of homologous proteins known as protein kinases (PKs), which catalyze the transfer of the terminal (or γ) phosphate of ATP to specific residues of protein substrates. The protein kinase family comprises two major subfamilies: the protein tyrosine kinases and the protein serine–threonine kinases. Recently, histidine kinases, which phosphorylate an imidazole nitrogen on a histidine residue, have also emerged as signaling enzymes <ce:cross-ref refid="BIB6">[6]</ce:cross-ref>. The protein tyrosine kinases (PTKs) activate numerous signaling pathways within cells, leading to cell proliferation, differentiation, migration and metabolic changes <ce:cross-ref refid="BIB7">[7]</ce:cross-ref>. They include receptor tyrosine kinases (RTKs, such as the insulin-receptor tyrosine kinase, IRK, or the epidermal growth factor receptor kinase, EGFR-K) and non-receptor tyrosine kinases (NRTKs), which include Src, JAKs and Abl, among others. RTKs are transmembrane glycoproteins that are composed of three major domains: an extracellular receptor domain, a membrane-spanning linker domain and a cytoplasmic domain, which contains the catalytic kinase activity. They are typically activated following the binding of a specific ligand to the receptor domain. The NRTKs are cytoplasmic proteins and are integral components of the signaling cascades triggered by RTKs and other cell surface receptors, such as G-protein coupled receptors and T-cell receptors <ce:cross-ref refid="BIB8">[8]</ce:cross-ref>. In addition to the PTK family, a large number of serine–threonine kinases have been identified. One well-characterized example is the family of the mitogen-activated protein kinases (MAPKs <ce:cross-ref refid="BIB9">[9]</ce:cross-ref>). To date, more than 530 kinase-related sequences have been identified in the human genome. For a comprehensive list of protein kinases, including sequence alignments, three-dimensional (3D) structural information and links to the genome, see the Protein Kinase Resource website at <ce:inter-ref xlink:href="http://pkr.sdsc.edu/html/index.shtml" xlink:type="simple">http://pkr.sdsc.edu/html/index.shtml.</ce:inter-ref>
               </ce:para>
               <ce:section view="all">
                  <ce:section-title>Structure of protein kinases</ce:section-title>
                  <ce:section view="all">
                     <ce:section-title>Overall structure</ce:section-title>
                     <ce:para view="all">All protein kinases contain a structurally conserved catalytic domain, which was first elucidated for the cyclic AMP-dependent kinase (PKA <ce:cross-ref refid="BIB10">[10]</ce:cross-ref>). Several crystal structures of protein kinases have been reported since then [the number of structures in the Protein Data Bank (PDB) as of October 2001 is 170 and includes structures of catalytic and regulatory domains] and the organization of the catalytic domain is now well established <ce:cross-ref refid="BIB11">[11]</ce:cross-ref>. It is composed of two major domains (N- and C-terminal domains; <ce:cross-ref refid="FIG1">Fig. 1</ce:cross-ref>
                        <ce:float-anchor refid="FIG1"/></ce:float-anchor>), that are further subdivided into 11 subdomains (color-coded in <ce:cross-ref refid="FIG1">Fig. 1</ce:cross-ref>). The two domains are connected through a single polypeptide strand (the linker region), which acts as a hinge about which the two domains can rotate with respect to one other upon binding of ATP and/or substrate, and without the disruption of the kinase's secondary structure. All protein kinases contain an aspartate residue (D166 in PKA) which has been implicated in the catalytic mechanism: this residue is located in the C-terminal domain in a loop termed the catalytic loop.</ce:para>
                     <ce:para view="all">Many protein kinases, but not all, require phosphorylation on one or more of the serine, threonine or tyrosine residues that are located in a segment running from the conserved DFG motif to the conserved APE motif (activation- or T-loop; <ce:cross-ref refid="FIG1">Fig. 1</ce:cross-ref>) <ce:cross-ref refid="BIB12">[12]</ce:cross-ref>. Phosphorylation of residues in the activation segment causes conformational changes in the protein that lead to the correct positioning of substrate binding residues and catalytic residues, and relief of steric blocking to enable access of substrates to the catalytic site. Protein kinases that are not regulated by phosphorylation have other mechanisms for localization of their activation segments, without the requirement of posttranslational modification <ce:cross-ref refid="BIB2">[2]</ce:cross-ref>. Although activation-loop phosphorylation is one way in which kinases are regulated, other control mechanisms recognized to date include: (1) control by additional subunits or domains that might function in response to second messengers (e.g. cyclic AMP binding to the regulatory subunit of PKA, or Ca<ce:sup loc="post">2?</ce:sup>–calmodulin binding to calmodulin-dependent protein kinase); (2) control by additional subunits whose level of expression varies depending on the functional state of the cell (e.g. cyclin regulation of the cyclin-dependent protein kinases, CDKs); (3) control by additional subunits that target the kinases to different molecules or subcellular localizations [e.g. the Src homology 2 and 3 (SH2 and SH3) domains of SRC kinases]; and (4) control by additional domains that inhibit kinase activity by autoregulatory processes [e.g. myosin light chain kinase (MLCK) or Src kinases].</ce:para>
                  </ce:section>
                  <ce:section view="all">
                     <ce:section-title>ATP-binding site</ce:section-title>
                     <ce:para view="all">ATP binds in a cleft between the two major domains and is anchored to the enzyme via hydrogen bonds between its adenine moiety and residues of the linker region, and the ribose ring and residues at the start of the C-terminal domain. The triphosphate group is coordinated by two metal ions that are ligated by Asp and/or Asn residues located in the DFG motif and the catalytic loop. In addition, polar interactions with several residues of the glycine-rich loop, the conserved DFG motif and the catalytic loop further stabilize the phosphates and the transition state that is generated during the phosphotransfer reaction. In contrast to the well-defined ATP-binding site, the substrate-binding regions of kinases are shallow surface depressions, whose structures are poorly understood and have not been used as targets for inhibitor binding. Substrate recognition and high-affinity binding rely partly on local residues, but in many cases it has become apparent that short peptide sequences do not exploit the complete binding capacity offered by the protein kinases. This suggests that kinases might use distal recognition elements that are likely to be important for efficient phosphorylation <ce:cross-ref refid="BIB13">[13]</ce:cross-ref>.</ce:para>
                     <ce:para view="all">It is known that several diseases can arise from, or involve, faulty protein kinase activity. For example, in humans, PTKs have a significant role in the development of many disease states, including diabetes and cancer, and have been also linked to a wide variety of congenital syndromes <ce:cross-ref refid="BIB14">[14]</ce:cross-ref>. Many different tumor types have been related to dysfunctional RTK, with consequent overactivity of the RPTK system. The overexpression or aberrant activity of NRTKs can also lead to alterations in signal transduction pathways: for example, Src kinases have been implicated in the pathology of tumors, osteoclast-mediated bone resorption and disorders associated with T-cell proliferation. Serine–theronine kinases also represent a large class of kinases for drug discovery opportunities: for example, MAP kinase p38 activation by proinflammatory cytokines and environmental stress has been associated with inflammatory processes, such as the initiation and progression of rheumatoid arthritis <ce:cross-ref refid="BIB15">[15]</ce:cross-ref>. Therefore, modulation of protein kinase activity represents an attractive area for the design of new therapeutic agents.</ce:para>
                  </ce:section>
               </ce:section>
               <ce:section view="all">
                  <ce:section-title>Kinase inhibition</ce:section-title>
                  <ce:para view="all">Although the catalytic core of protein kinases has been evolutionarily conserved <ce:cross-ref refid="BIB11">[11]</ce:cross-ref>, the mechanisms by which the inhibition of each kinase is achieved might vary considerably. Physiologically, at least three inhibition mechanisms have been identified: a pseudo-substrate mechanism, an adenine mimetic mechanism and a mechanism that involves locking the enzyme into an inactive conformation by using surfaces other than the active site <ce:cross-ref refid="BIB16">[16]</ce:cross-ref>. Chemically, the field of protein-kinase inhibition has been highly active in the past 10 years and, to date, several synthetic pharmacophores have been identified as potent kinase inhibitors. Given the different nature of the nucleotide- and substrate-binding sites outlined previously, much of the synthetic effort has been devoted to the ATP-binding site, and the great majority of reported inhibitors are adenine mimetics <ce:cross-refs refid="BIB17 BIB18 BIB19 BIB20 BIB21 BIB22">[17–22]</ce:cross-refs>, although several examples of inhibitors directed to noncatalytic domains of PTKs exist <ce:cross-refs refid="BIB23 BIB24 BIB25 BIB26">[23–26]</ce:cross-refs>. By contrast, the protein substrate-binding site has not been extensively exploited for inhibitor design <ce:cross-ref refid="BIB21">[21]</ce:cross-ref>, even though compounds that block the enzyme function by substrate competition might have an advantage over ATP mimetics, that for several reasons, including the fact that the high intracellular concentration of ATP could reduce the efficacy of ATP mimics, and that substrate-competitive inhibitors are likely to be more specific and selective. Recently, small substrate-competitive inhibitors of the insulin-like growth factor-1 (IGF-1R) and insulin receptor (IR) kinases have been described <ce:cross-refs refid="BIB27 BIB28">[27,28]</ce:cross-refs>.</ce:para>
                  <ce:para view="all">Several excellent reviews covering the chemistry and biology of kinase inhibitors have been published in the past few years <ce:cross-refs refid="BIB17 BIB22 BIB29 BIB30">[17,22,29,30]</ce:cross-refs>. Here, we will briefly describe the specific efforts that have resulted in the structure-based design of PK inhibitors; for example, the design or optimization of a small-molecule inhibitor based on the knowledge of the protein structure and specific protein–ligand interactions. It is worth noting that, although all the structures reported here are referred to as being obtained by structure-based design efforts, they are never solely the product of this approach, but rather a combination of crystallography, modeling, screening and medicinal chemistry efforts. As such, it might sometimes be more appropriate to define them as structure-assisted designs.</ce:para>
               </ce:section>
               <ce:section view="all">
                  <ce:section-title>ATP-competitive inhibitors</ce:section-title>
                  <ce:para view="all">A great majority of the kinase inhibitors presented in this and other reviews are ATP-competitive. Therefore, selectivity becomes an important issue in the development of safe drugs because protein kinases share common sequences and structural homology in their ATP-binding site. In addition, there are many other proteins encoded by the human genome that rely on purine-based co-factors. Nevertheless, several ATP-site directed and highly selective inhibitors are currently in various stages of drug development. With regards to kinase specificity, only a fraction of all known kinases are screenable at present; for this reason, and assuming that it is virtually impossible to design a completely selective ATP mimic, the concept of a ‘kinase profile’ rather than specific kinase inhibition has recently been used in drug discovery as a better way to obtain a pharmacological response <ce:cross-ref refid="BIB31">[31]</ce:cross-ref>. The numerous structures of complexes with ATP, its analog AMP.PNP, or small-molecule inhibitors bound to different protein kinases have provided a clear description of the ATP-binding cleft and of the similarities and differences that exist within the binding region. It is now clear that there are regions within the binding cleft that are not occupied by ATP, and that these regions (namely, the hydrophobic regions 1 and 2; <ce:cross-ref refid="FIG2">Fig. 2</ce:cross-ref>
                     <ce:float-anchor refid="FIG2"/></ce:float-anchor>) show structural diversity between members of the kinase family <ce:cross-ref refid="BIB18">[18]</ce:cross-ref>. In several cases, the structural biology efforts clearly show that compounds already known to be selective for a specific kinase (e.g. p38 <ce:cross-ref refid="BIB32">[32]</ce:cross-ref>) or kinase class (e.g. the Src family kinases <ce:cross-refs refid="BIB33 BIB34 BIB35">[33–35]</ce:cross-refs>), targeted the poorly conserved areas of the ATP-binding site, thus providing a structural basis for the observed selectivity. By contrast, the conserved nature of the kinase core makes it an excellent candidate for homology modeling, in which the sequence of the conserved core of a new kinase can be modeled onto a 3D template. As more structures are determined, the accuracy of the modeling and the possibility of using this approach for inhibitor design will improve. Although the efforts in exploiting this structural knowledge for the design of novel and selective inhibitors have been somewhat limited (for example, compared to medicinal chemistry efforts), structure-based design approaches have played an important role in the identification of new lead structures and in the successful derivatization of ‘classical kinase templates’.</ce:para>
                  <ce:section view="all">
                     <ce:section-title>Cyclin-dependent kinases</ce:section-title>
                     <ce:para view="all">Cyclin-dependent kinases have a crucial role in regulating the cell cycle and constitute potential targets in anticancer drug research <ce:cross-refs refid="BIB36 BIB37">[36,37]</ce:cross-refs>. Small molecules of different chemical types have been reported to inhibit CDKs, for example, olomoucine (<ce:cross-ref refid="FIG3">Fig. 3</ce:cross-ref>
                        <ce:float-anchor refid="FIG3"/></ce:float-anchor>; <ce:bold>i</ce:bold>) and flavopiridol (<ce:cross-ref refid="FIG3">Fig. 3</ce:cross-ref>; <ce:bold>ii</ce:bold>); flavopiridol is a semisynthetic flavonoid that emerged from an empirical screening program and is undergoing clinical evaluation <ce:cross-ref refid="BIB38">[38]</ce:cross-ref>. Crystal structures of CDK2 with both compounds bound have been determined <ce:cross-refs refid="BIB39 BIB40">[39,40]</ce:cross-refs>. Using these data, Furet <ce:italic>et al.</ce:italic> 
                        <ce:cross-refs refid="BIB41 BIB42">[41,42]</ce:cross-refs> developed a structure-based drug design approach to improve the potency of olomoucine-derived compounds and to find different structural classes of CDK1 inhibitors. Based on CDK2 structures, they constructed a 3D model of the ATP-binding pocket of CDK1 bound to olomoucine. This model was used to design modifications at the synthetically accessible N9, N6 and C2 positions (<ce:cross-ref refid="FIG3">Fig. 3</ce:cross-ref>). This approach resulted in the design of compounds (e.g. <ce:bold>iii</ce:bold>; <ce:cross-ref refid="FIG3">Fig. 3</ce:cross-ref>), which are several orders of magnitude more potent than olomoucine and retained the selectivity profile displayed by olomoucine. Analysis of the binding mode of olomoucine and flavopiridol to CDK2 enabled the design of an ATP-site directed ligand scaffold that facilitated the identification of new, potent inhibitors of CDK1 in subsequent database searching. Testing of the newly discovered naphthoquinone compounds (<ce:cross-ref refid="FIG3">Fig. 3</ce:cross-ref>; <ce:bold>iv</ce:bold>) showed that they were at least equipotent to <ce:bold>i</ce:bold> and <ce:bold>ii</ce:bold>, and that they were characterized by some degree of selectivity for CDK1 over a panel of other kinases (CDK4, PKCα, PKA and EGF-R). One of the compounds was also shown to be equipotent to flavopiridol in inhibiting the proliferation of human bladder carcinoma T24 cells <ce:italic>in vitro.</ce:italic> The structure of one analog of <ce:bold>iv</ce:bold> bound to CDK2 was also determined, confirming that the binding mode was the one predicted by the design hypothesis for naphthoquinone inhibitors. A similar homology modeling approach, together with quantum mechanical calculations, was used by Gussio <ce:italic>et al.</ce:italic> 
                        <ce:cross-ref refid="BIB43">[43]</ce:cross-ref> in the modification of a paullone scaffold (<ce:cross-ref refid="FIG3">Fig. 3</ce:cross-ref>; <ce:bold>v</ce:bold>) for the design of CDK inhibitors. The electronic properties derived from the calculations helped direct synthetic chemistry efforts to produce ligands that promote better charge transfer and strengthen hydrogen bonding as facilitated by resonance stabilization. This approach resulted in the discovery of a 9-nitropaullone with nanomolar potency in enzyme inhibition and a favorable anti-proliferative activity profile in living cells.</ce:para>
                     <ce:para view="all">Another way to exploit available crystallographic information, which has been used in the design of CDK2 inhibitors, is the structure-based design of combinatorial libraries, representing an effective way to either improve inhibitor discovery or improve potency of already known inhibitors. From structural studies, it was shown that olomoucine binds to CDK2 with the purine ring rotated by ∼160° with respect to the adenine ring in ATP. Based on this compariso∼n, three purine sites (positions 2, 6 and 9) were identified, the modification of which could potentially lead to improved binding affinity and selectivity. The best inhibitors identified from the libraries were approximately three orders of magnitude more potent than the parent compound <ce:cross-refs refid="BIB44 BIB45">[44,45]</ce:cross-refs>. Ikuta and co-workers <ce:cross-ref refid="BIB46">[46]</ce:cross-ref> took the homology modeling concept one step further and synthesized a CDK4-mimic CDK2 protein in which the ATP-binding pocket of CDK2 was replaced by the one in CDK4 by mutating three non-conserved residues. The mutant protein was crystallized in both the ligand-free and ligand-bound form, and the derived structural information was used to design and synthesize a CDK4-specific inhibitor with essentially no CDK2 activity.</ce:para>
                  </ce:section>
                  <ce:section view="all">
                     <ce:section-title>ErbB/EGFR kinase</ce:section-title>
                     <ce:para view="all">Members of the EGFR family are transmembrane proteins whose overexpression in cancer cells has been associated with excessive proliferation and metastasis <ce:cross-ref refid="BIB47">[47]</ce:cross-ref>. The EGFR is often used as a tumor prognostic marker, because its overexpression has been correlated with a poor prognosis in several tumor types. As well as being an ideal and viable target in cancer drug discovery programs, the role of EGFR in cell proliferation makes it an attractive target in other hyperproliferative disorders, such as psoriasis. Furet <ce:italic>et al.</ce:italic> 
                        <ce:cross-ref refid="BIB48">[48]</ce:cross-ref> published the first data of a pharmacophore model for inhibitors competing for the ATP-binding site of the EGFR kinase. This pharmacophore model was used successfully for the design and synthesis of 4-phenylamino-pyrrolo[2,3-<ce:italic>d</ce:italic>]pyrimidines, 4-phenylaminopyrazolo[2,3-<ce:italic>d</ce:italic>]pyrimidines, substituted isoflavones and 3-phenyl-4(1<ce:italic>H</ce:italic>)-quinolones. These compounds have EGFR-kinase inhibitory activity with IC<ce:inf loc="post">50</ce:inf> values of 1–5 nm <ce:cross-ref refid="BIB49">[49]</ce:cross-ref>. In a similar approach, a homology model of the EGFR-kinase catalytic domain was built based on the structural alignment of the EGFR sequence with the sequences of known crystal structures of several other protein kinases; this model was then used in combination with molecular docking methods to identify analogs of the active metabolite of leflunomide (LFM; <ce:bold>vi</ce:bold>, <ce:cross-ref refid="FIG4">Fig. 4</ce:cross-ref>
                        <ce:float-anchor refid="FIG4"/></ce:float-anchor>) with potent and specific inhibitory activity against EGFR (LFM-A12; <ce:bold>vii</ce:bold>, <ce:cross-ref refid="FIG4">Fig. 4</ce:cross-ref>) <ce:cross-ref refid="BIB50">[50]</ce:cross-ref>. Interestingly, the same lead compound (<ce:bold>vi</ce:bold>) was used as a starting point to design Bruton's tyrosine kinase (BTK) inhibitors, which were then evaluated using a 3D homology model for the BTK domain and molecular docking procedures. This process resulted in the identification of LFM-A13 (<ce:bold>viii</ce:bold>; <ce:cross-ref refid="FIG4">Fig. 4</ce:cross-ref>), which, although very similar to LFM-A12, is a remarkably selective inhibitor of BTK and does not show any activity compared with the EGFR kinase <ce:cross-ref refid="BIB51">[51]</ce:cross-ref>. The model of the EGFR-binding pocket was also used in combination with docking procedures to estimate K<ce:inf loc="post">i</ce:inf> values (based on the binding interaction between the inhibitor and the catalytic pocket of EGFR) and design substitutions for another class of EGFR inhibitors, the 4-anilinoquinazolines (<ce:cross-ref refid="FIG4">Fig. 4</ce:cross-ref>; <ce:bold>ix</ce:bold> and <ce:bold>x</ce:bold>). Both LFM- and quinazoline-derived compounds inhibited the proliferation and <ce:italic>in vitro</ce:italic> invasiveness of EGFR-positive human breast-cancer cells. However, unlike the LFM-derived compounds, the quinazoline compounds were not specific for EGFR <ce:cross-ref refid="BIB50">[50]</ce:cross-ref>.</ce:para>
                     <ce:para view="all">Using a slightly different approach, selective, potent and irreversible inhibitors of the erbB receptor subfamily were designed using an extensive comparative analysis of sequence conservation between the Ser–Thr and Tyr kinases in the context of the structure of the cAMP dependent Ser–Thr kinase. This enabled the identification of a conserved Cys residue in the nucleotide-binding site of the erbB receptor family and the design of a thioadenosine that covalently inactivates erbB-1 (or epidermal growth factor receptor, EGFR <ce:cross-ref refid="BIB52">[52]</ce:cross-ref>).</ce:para>
                  </ce:section>
                  <ce:section view="all">
                     <ce:section-title>Janus kinase 3</ce:section-title>
                     <ce:para view="all">Members of the Janus family of tyrosine kinases (JAKs) activate a family of DNA-binding proteins known as STATs (signal transducers and activators of transcription) <ce:cross-ref refid="BIB53">[53]</ce:cross-ref>, that have a dual role as signaling molecules and transcription factors. JAKs are abundantly expressed in primary leukemic cells from children with acute lymphoblastic leukemia and represent a potential target for treatment of leukemias with hyperactive JAK–STAT signaling machinery <ce:cross-ref refid="BIB54">[54]</ce:cross-ref>. The structure-based design of inhibitors of JAK3 is described by Sudbeck and co-workers <ce:cross-ref refid="BIB55">[55]</ce:cross-ref>. After constructing a homology model for the kinase domain of JAK3, modeling and docking studies were used to predict how well potential inhibitors could fit into and bind to its catalytic site. The modeling studies suggested that 4-(phenyl)-amino-6,7-dimethoxyquinazoline compounds with an OH group at the 4′ position of the phenyl ring would most strongly bind to JAK3 because of the added interactions with Asp967. These compounds inhibited JAK3 in immune complex kinase assays in a dose-dependent fashion, with K<ce:inf loc="post">i</ce:inf> values between 0.6 and 2.3 μm, while compounds lacking the 4′-OH did not show any significant JAK3 inhibition. Furthermore, the lead dimethoxyquinazoline compound did not inhibit JAK1, JAK2, SYK (spleen tyrosine kinase), BTK, LYN (LCK-related kinase) or the insulin receptor kinases. The same compound was shown to inhibit the clonogenic growth of JAK3-positive leukemia cell lines DAUDI, RAMOS, LC119, NALM6, MOLT3 and HL60 (but not JAK3-negative BT20 breast cancer, M24-MET melanoma or SQ20B squamous carcinoma cell lines) in a concentration-dependent fashion.</ce:para>
                  </ce:section>
                  <ce:section view="all">
                     <ce:section-title>Abl kinase</ce:section-title>
                     <ce:para view="all">Random-screening identified a phenylamino-pyrimidine compound (<ce:cross-ref refid="FIG5">Fig. 5</ce:cross-ref>
                        <ce:float-anchor refid="FIG5"/></ce:float-anchor>; <ce:bold>xi</ce:bold>) as an unselective, submicromolar inhibitor against PKCα. Simple modifications of this lead compound led to compounds that completely lost the PKCα activity, but were dual Abl–PDGFR kinase inhibitors. This eventually led to the development of CGP57148, or STI571 <ce:cross-ref refid="BIB49">[49]</ce:cross-ref> (<ce:cross-ref refid="FIG5">Fig. 5</ce:cross-ref>; <ce:bold>xii</ce:bold>), a potent and selective Abl kinase (Abl-K) inhibitor, which has been recently approved by the FDA for the treatment of chronic myelogenous leukemia [caused by the inadvertent activation of the Abl-K by fusion of the corresponding gene (<ce:italic>Abl</ce:italic>) to a segment of the downstream <ce:italic>bcr</ce:italic> gene]. The structure of an STI571 analog bound to the catalytic domain of Abl-K <ce:cross-ref refid="BIB56">[56]</ce:cross-ref> provides a structural mechanism for the selective inhibition of Abl-K. Crucial to the binding of the compound is the adoption by the kinase of an inactive conformation in which the activation loop is not phosphorylated. The conformation of the loop is distinct from that observed in activated PTKs, as well as from that observed in the inactive form of the closely related Src kinase. Although the previous ATP-competitive inhibitor was not identified with the help of a pharmacophore model, it exemplifies the ATP-binding site of protein kinases as an exciting target, and shows that minor modifications of a molecule's structure and its mode of interaction with the target enzyme can lead to major changes in the selectivity profile. These results also suggest that compounds that exploit the distinctive inactivation mechanism of individual protein kinases can achieve both high affinity and high selectivity.</ce:para>
                  </ce:section>
               </ce:section>
               <ce:section view="all">
                  <ce:section-title>Inhibition of intra-macromolecular interactions</ce:section-title>
                  <ce:para view="all">Signaling by PTKs involves a regulated series of protein–protein and protein–membrane interactions mediated by a variety of conserved protein modules, including the Scr SH3 and SH2 domains, the C1A and C1B subdomains of PKC, as well as a variety of other motifs <ce:cross-refs refid="BIB57 BIB58 BIB59 BIB60">[57–60]</ce:cross-refs>. This type of protein–protein interaction is another potential target for the rational design of inhibitors. Such inhibitors could be used to elucidate the roles of their target molecules in cellular functions, and to evaluate their potential as targets for therapeutic intervention.</ce:para>
                  <ce:section view="all">
                     <ce:section-title>SH3 domains</ce:section-title>
                     <ce:para view="all">Src homology 3 domains are small (55–70 amino acid) non-catalytic protein modules that mediate protein–protein interactions by binding to proline-rich sequences. The interaction requires the minimal consensus sequence PxxP (<ce:cross-ref refid="FIG6">Fig. 6</ce:cross-ref>
                        <ce:float-anchor refid="FIG6"/></ce:float-anchor>a). Originally discovered as a homology domain present in the tryosine kinase v-Src, SH3 domains have now been found in numerous intracellular proteins, including kinases, lipases, GTPases, adapter proteins, structural proteins and viral regulatory proteins. X-ray and/or NMR methods have determined numerous SH3 domain structures and such studies have revealed that the ligand binds to the SH3 domain in a left-handed type II polyproline helix conformation. The ligand can interact with the SH3 domain in one of two orientations, depending on the position (N- versus C-terminal) of its proline-rich sequence <ce:cross-refs refid="BIB58 BIB61">[58,61]</ce:cross-refs>. Core SH3 ligands are characterized by weak interactions (K<ce:inf loc="post">d</ce:inf>=5–100 μm) that show little binding selectivity within SH3 families. Higher affinity, more selective ligands require additional flanking residues that bind to less conserved portions of the SH3 surface. Most of the efforts in designing potent and SH3-selective compounds have been based on the use of combinatorial libraries to target either the N-terminal end of the cognate peptide, or the internal Pro-Pro fragment <ce:cross-refs refid="BIB62 BIB63">[62,63]</ce:cross-refs>. Although these efforts resulted in the synthesis of peptidomimetics, to date there are no reports of non-peptidyl small molecule SH3 inhibitors.</ce:para>
                  </ce:section>
                  <ce:section view="all">
                     <ce:section-title>SH2 domains</ce:section-title>
                     <ce:para view="all">Src homology 2 domains are non-catalytic motifs of ∼100 amino acids that specifically bind phosphotyrosine residues (pTyr), with an affinity that is dependent on the amino acid sequence C-terminal to the pTyr motif <ce:cross-refs refid="BIB58 BIB64">[58,64]</ce:cross-refs>. All the SH2 domains determined to date share common structural properties, including a central antiparallel β-sheet core, flanked on each side by an α-helix (<ce:cross-ref refid="FIG6">Fig. 6</ce:cross-ref>b). The phosphorylated ligand binds perpendicular to the β-sheet and typically interacts with two well-defined binding pockets: the pTyr binding pocket and a hydrophobic pocket that interacts with the pY+3 side chain (<ce:cross-ref refid="FIG6">Fig. 6</ce:cross-ref>c). Inhibitors of specific SH2 domains have become important therapeutic targets in the treatment and/or prevention of several diseases, including restenosis, cancers, cardiovascular disease and osteoporosis <ce:cross-ref refid="BIB25">[25]</ce:cross-ref>. In most cases, peptide libraries have generated the initial ligands; the subsequent use of structural information has been crucial in understanding the mode of binding of these inhibitors and the design of second-generation compounds. Several examples of novel, non-peptide inhibitors of the Scr SH2 domain, designed on the basis of X-ray crystal structures, have been described <ce:cross-refs refid="BIB65 BIB66 BIB67">[65–67]</ce:cross-refs>. In each case, the X-ray crystal structure of one or more of the inhibitors bound to the SH2 domain confirmed the interactions targeted but also revealed a unique mode of binding for the pTyr analog, which could be further exploited for optimization of the compounds <ce:cross-ref refid="BIB65">[65]</ce:cross-ref>. Modeling, and the crystal structures of phosphopeptides bound to SH2 domains, helped in the design of second-generation inhibitors (<ce:cross-ref refid="FIG7">Fig. 7</ce:cross-ref>
                        <ce:float-anchor refid="FIG7"/></ce:float-anchor>; <ce:bold>xiii</ce:bold> and <ce:bold>xiv</ce:bold>), which represent some of the tightest binding inhibitors for this SH2 domain <ce:cross-ref refid="BIB67">[67]</ce:cross-ref>. Further modification of this series produced a compound (<ce:cross-ref refid="FIG7">Fig. 7</ce:cross-ref>; <ce:bold>xv,</ce:bold> AP22408) that demonstrates <ce:italic>in vivo</ce:italic> inhibition of osteoclast-mediated bone resorption <ce:cross-ref refid="BIB68">[68]</ce:cross-ref>.</ce:para>
                     <ce:para view="all">Another system for which the structure-based design of SH2 inhibitors produced suitable antagonists is the adaptor protein Grb2. The SH2 domain of Grb2 serves as a crucial link between various growth factor receptors and <ce:italic>ras</ce:italic> proteins. In recent years, intracellular signaling events involving <ce:italic>ras</ce:italic> proteins have been directly implicated in many oncogenic processes, suggesting that Grb2–SH2 domain inhibitors could be useful in cancer research. As reported for the c-Src SH2, the initial leads for the Grb2–SH2 inhibitors were derived from minimal peptide sequences (<ce:cross-ref refid="FIG8">Fig. 8</ce:cross-ref>
                        <ce:float-anchor refid="FIG8"/></ce:float-anchor>; <ce:bold>xvi</ce:bold>). The X-ray structure of the Grb2–SH2 domain in complex with a specific phosphopeptide ligand revealed an extended hydrophobic area adjacent to the primary-binding site of the ligand on the SH2 domain. This feature has been exploited to design hydrophobic C-terminal groups that improve the binding affinity of the minimal sequence pTyr-Ile-Asn recognized by the Grb2–SH2 domain. This modification, combined with replacement of the isoleucine residue by 1-aminocyclohexane carboxylic acid to stabilize the β-turn conformation, which is required for recognition by the Grb2–SH2 domain, resulted in the high affinity (47 nm in an ELISA assay) and selective (over a variety of other SH2 domains) phosphopeptide (<ce:cross-ref refid="FIG8">Fig. 8</ce:cross-ref>; <ce:bold>xvii</ce:bold>) <ce:cross-ref refid="BIB69">[69]</ce:cross-ref>. To further reduce the peptidic character of the compound, the Asn residue was successfully replaced by a six-membered ring β-amino acid, designed on the basis of the Asn side conformation and hydrogen-bonding pattern. This new antagonist (<ce:cross-ref refid="FIG8">Fig. 8</ce:cross-ref>; <ce:bold>xviii</ce:bold>) maintained the activity observed for its precursor (3-amino-<ce:italic>Z</ce:italic>-pTyr-Ac<ce:inf loc="post">6</ce:inf>c-Asn-NH<ce:inf loc="post">2</ce:inf>) <ce:cross-ref refid="BIB70">[70]</ce:cross-ref>.</ce:para>
                  </ce:section>
                  <ce:section view="all">
                     <ce:section-title>C1B domain of PKC</ce:section-title>
                     <ce:para view="all">PKC is a signaling enzyme that has been proposed to have an important role in carcinogenesis, metastasis and chemotherapy-associated multidrug resistance. A recent review <ce:cross-ref refid="BIB71">[71]</ce:cross-ref> summarizes several lines of evidence suggesting that the expression of constitutive PKCα activity is required for the survival of human prostate cancer cells, thereby proposing that PKCα could serve as a novel target in the treatment of prostate cancer. Based upon the structure of the potent PKC activator 8-decynylbenzolactam (<ce:cross-ref refid="FIG9">Fig. 9</ce:cross-ref>
                        <ce:float-anchor refid="FIG9"/></ce:float-anchor>; <ce:bold>xix</ce:bold>) and the X-ray structures of the second activator-binding domain of PKCδ (C1B domain) in complex with phorbol 13-acetate, Qiao and co-workers <ce:cross-ref refid="BIB60">[60]</ce:cross-ref> designed a new class of rigidified pyrrolidone-based PKC activators. These compounds maintain the hydrogen-bond network and hydrophobic interactions crucial for binding to C1B, and were found to possess reasonably good affinity for PKC and, in a few cases, some isoenzyme selectivity. One of these pyrrolidone compounds (<ce:cross-ref refid="FIG9">Fig. 9</ce:cross-ref>; <ce:bold>xx</ce:bold>) was shown to induce a dose-dependent induction of apoptosis in LNCaP prostate cancer cells.</ce:para>
                  </ce:section>
               </ce:section>
               <ce:section view="all">
                  <ce:section-title>Conclusions</ce:section-title>
                  <ce:para view="all">Several examples exist in the recent literature of structure-based drug design, which rely on some knowledge of a protein kinase's 3D structure to design and/or optimize specific inhibitors. Most of the studies use homology models, which can only approximate the actual target structure but are becoming more and more accurate as the number of kinase crystal structures are solved. The structure-based design of a new compound is almost never a <ce:italic>de novo</ce:italic> process, but more often a modification of existing leads, both naturally occurring (ATP, peptide substrates, natural products) or found by conventional biochemical screening. One potential pitfall of relying solely on structural considerations to design preclinical candidates is that structure-based drug design might provide inhibitors that are extremely potent and selective <ce:italic>in vitro</ce:italic>, but with limited or no activity in tissue cultures or in animals. Nevertheless, the methods and results summarized in this review clearly illustrate the power of structure-based design in lead discovery (i.e. by virtual screening) and in the process of assisting the optimization of the pharmacological properties of these molecules.</ce:para>
               </ce:section>
            </ce:sections>
            <ce:acknowledgment>
               <ce:section-title>Acknowledgements</ce:section-title>
               <ce:para view="all">The author would like to thank J. W. Becker, R.S. Magliozzo and S.M. Soisson for critically reading the manuscript.</ce:para>
            </ce:acknowledgment>
         </body>
         <tail>
            <ce:bibliography view="all">
               <ce:section-title>References</ce:section-title>
               <ce:bibliography-sec>
                  <ce:bib-reference id="BIB1">
                     <ce:label>1.</ce:label>
                     <sb:reference>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T</ce:given-name>
                                 <ce:surname>Hunter</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Protein kinases and phosphatases: the yin and yang of protein phosphorylation and signaling</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>80</sb:volume-nr>
                              </sb:series>
                              <sb:date>1995</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>225</sb:first-page>
                              <sb:last-page>236</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="BIB2">
                     <ce:label>2.</ce:label>
                     <sb:reference>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.N</ce:given-name>
                                 <ce:surname>Johnson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.J</ce:given-name>
                                 <ce:surname>Lewis</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structural basis for control by phosphorylation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chem. Rev.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>101</sb:volume-nr>
                              </sb:series>
                              <sb:date>2001</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2209</sb:first-page>
                              <sb:last-page>2242</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="BIB3">
                     <ce:label>3.</ce:label>
                     <sb:reference>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.G</ce:given-name>
                                 <ce:surname>Neel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.K</ce:given-name>
                                 <ce:surname>Tonks</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Protein tyrosine phosphatases in signal transduction</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Opin. Cell. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>9</sb:volume-nr>
                              </sb:series>
                              <sb:date>1997</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>193</sb:first-page>
                              <sb:last-page>204</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="BIB4">
                     <ce:label>4.</ce:label>
                     <sb:reference>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.J</ce:given-name>
                                 <ce:surname>Kennelly</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Protein phosphatases – a phylogenetic perspective</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chem. Rev.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>101</sb:volume-nr>
                              </sb:series>
                              <sb:date>2001</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2291</sb:first-page>
                              <sb:last-page>2312</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="BIB5">
                     <ce:label>5.</ce:label>
                     <sb:reference>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.D</ce:given-name>
                                 <ce:surname>Jackson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M</ce:given-name>
                                 <ce:surname>Denu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Molecular reactions of protein phosphatases – insights from structure and chemistry</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chem. Rev.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>101</sb:volume-nr>
                              </sb:series>
                              <sb:date>2001</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2313</sb:first-page>
                              <sb:last-page>2340</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="BIB6">
                     <ce:label>6.</ce:label>
                     <sb:reference>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H</ce:given-name>
                                 <ce:surname>Saito</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Histidine phosphorylation and two-component signaling in eukaryotic cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chem. Rev.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>101</sb:volume-nr>
                              </sb:series>
                              <sb:date>2001</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2497</sb:first-page>
                              <sb:last-page>2510</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="BIB7">
                     <ce:label>7.</ce:label>
                     <sb:reference>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J</ce:given-name>
                                 <ce:surname>Schlessinger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A</ce:given-name>
                                 <ce:surname>Ullrich</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Growth factor signaling by receptor tyrosine kinases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Neuron</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>9</sb:volume-nr>
                              </sb:series>
                              <sb:date>1992</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>383</sb:first-page>
                              <sb:last-page>391</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="BIB8">
                     <ce:label>8.</ce:label>
                     <sb:reference>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.R</ce:given-name>
                                 <ce:surname>Hubbard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.H</ce:given-name>
                                 <ce:surname>Till</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Protein tyrosine kinase structure and function</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Annu. Rev. Biochem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>69</sb:volume-nr>
                              </sb:series>
                              <sb:date>2000</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>373</sb:first-page>
                              <sb:last-page>398</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="BIB9">
                     <ce:label>9.</ce:label>
                     <sb:reference>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Z</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>MAP kinases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chem. Rev.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>101</sb:volume-nr>
                              </sb:series>
                              <sb:date>2001</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2449</sb:first-page>
                              <sb:last-page>2476</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="BIB10">
                     <ce:label>10.</ce:label>
                     <sb:reference>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.R</ce:given-name>
                                 <ce:surname>Knighton</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structure of a peptide inhibitor bound to the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Science</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>253</sb:volume-nr>
                              </sb:series>
                              <sb:date>1991</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>407</sb:first-page>
                              <sb:last-page>414</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="BIB11">
                     <ce:label>11.</ce:label>
                     <sb:reference>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.K</ce:given-name>
                                 <ce:surname>Hanks</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T</ce:given-name>
                                 <ce:surname>Hunter</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>FASEB J.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>9</sb:volume-nr>
                              </sb:series>
                              <sb:date>1995</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>576</sb:first-page>
                              <sb:last-page>596</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="BIB12">
                     <ce:label>12.</ce:label>
                     <sb:reference>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.N</ce:given-name>
                                 <ce:surname>Johnson</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Active and inactive protein kinases: structural basis for regulation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>85</sb:volume-nr>
                              </sb:series>
                              <sb:date>1996</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>149</sb:first-page>
                              <sb:last-page>158</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="BIB13">
                     <ce:label>13.</ce:label>
                     <sb:reference>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.A</ce:given-name>
                                 <ce:surname>Adams</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Kinetic and catalytic mechanisms of protein kinases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chem. Rev.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>101</sb:volume-nr>
                              </sb:series>
                              <sb:date>2001</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2271</sb:first-page>
                              <sb:last-page>2290</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="BIB14">
                     <ce:label>14.</ce:label>
                     <sb:reference>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.C</ce:given-name>
                                 <ce:surname>Robertson</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>RTK mutations and human syndromes: when good receptors turn bad</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Trends Genet.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>16</sb:volume-nr>
                              </sb:series>
                              <sb:date>2000</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>265</sb:first-page>
                              <sb:last-page>271</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="BIB15">
                     <ce:label>15.</ce:label>
                     <sb:reference>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>U</ce:given-name>
                                 <ce:surname>Muller-Ladner</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Molecular and cellular interactions in rheumatoid synovium</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Opin. Rheumathol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:date>1996</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>210</sb:first-page>
                              <sb:last-page>220</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="BIB16">
                     <ce:label>16.</ce:label>
                     <sb:reference>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.S</ce:given-name>
                                 <ce:surname>Taylor</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E</ce:given-name>
                                 <ce:surname>Radzio-Andzelm</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Protein kinase inhibition: natural and synthetic variations on a theme</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Opin. Chem. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>1</sb:volume-nr>
                              </sb:series>
                              <sb:date>1997</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>219</sb:first-page>
                              <sb:last-page>226</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="BIB17">
                     <ce:label>17.</ce:label>
                     <sb:reference>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.I</ce:given-name>
                                 <ce:surname>Bridges</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Chemical inhibitors of protein kinases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chem. Rev.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>101</sb:volume-nr>
                              </sb:series>
                              <sb:date>2001</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2541</sb:first-page>
                              <sb:last-page>2572</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="BIB18">
                     <ce:label>18.</ce:label>
                     <sb:reference>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.M</ce:given-name>
                                 <ce:surname>Toledo</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The structure-based design of ATP-site directed protein kinases inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>6</sb:volume-nr>
                              </sb:series>
                              <sb:date>1999</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>775</sb:first-page>
                              <sb:last-page>805</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="BIB19">
                     <ce:label>19.</ce:label>
                     <sb:reference>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.M</ce:given-name>
                                 <ce:surname>Traxler</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Protein tyrosine kinase inhibitors in cancer treatment</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Exp. Opin. Ther. Patents</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>7</sb:volume-nr>
                              </sb:series>
                              <sb:date>1997</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>571</sb:first-page>
                              <sb:last-page>588</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="BIB20">
                     <ce:label>20.</ce:label>
                     <sb:reference>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.M</ce:given-name>
                                 <ce:surname>Traxler</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Protein tyrosine kinase inhibitors in cancer treatment (part II)</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Exp. Opin. Ther. Patents</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:date>1998</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1599</sb:first-page>
                              <sb:last-page>1625</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="BIB21">
                     <ce:label>21.</ce:label>
                     <sb:reference>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.S</ce:given-name>
                                 <ce:surname>Lawrence</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J</ce:given-name>
                                 <ce:surname>Niu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Protein kinase inhibitors: the tyrosine-specific protein kinases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Pharmacol. Ther.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>77</sb:volume-nr>
                              </sb:series>
                              <sb:date>1998</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>81</sb:first-page>
                              <sb:last-page>114</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="BIB22">
                     <ce:label>22.</ce:label>
                     <sb:reference>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J</ce:given-name>
                                 <ce:surname>Dumas</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Protein kinase inhibitors: emerging pharmacophores 1997–2000</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Exp. Opin. Ther. Patents</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>11</sb:volume-nr>
                              </sb:series>
                              <sb:date>2001</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>405</sb:first-page>
                              <sb:last-page>429</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="BIB23">
                     <ce:label>23.</ce:label>
                     <sb:reference>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.J</ce:given-name>
                                 <ce:surname>Broadbridge</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.P</ce:given-name>
                                 <ce:surname>Sharma</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The Src homology-2 domains (SH2 domains) of the protein tyrosine kinase p56lck: structure, mechanism and drug design</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Current Drug Targets</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>1</sb:volume-nr>
                              </sb:series>
                              <sb:date>2000</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>365</sb:first-page>
                              <sb:last-page>386</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="BIB24">
                     <ce:label>24.</ce:label>
                     <sb:reference>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.B</ce:given-name>
                                 <ce:surname>Vu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Recent advances in the design and synthesis of SH2 inhibitors of Src, Grb2 and ZAP-70</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>7</sb:volume-nr>
                              </sb:series>
                              <sb:date>2000</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1081</sb:first-page>
                              <sb:last-page>1100</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="BIB25">
                     <ce:label>25.</ce:label>
                     <sb:reference>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.L</ce:given-name>
                                 <ce:surname>Cody</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Progress in the development of inhibitors of SH2 domains</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Pharm. Design</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>6</sb:volume-nr>
                              </sb:series>
                              <sb:date>2000</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>59</sb:first-page>
                              <sb:last-page>98</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="BIB26">
                     <ce:label>26.</ce:label>
                     <sb:reference>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R-H</ce:given-name>
                                 <ce:surname>Yeh</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>From consensus sequence peptide to high affinity ligand, a ‘library scan’ strategy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Biol. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>276</sb:volume-nr>
                              </sb:series>
                              <sb:date>2001</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>12235</sb:first-page>
                              <sb:last-page>12240</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="BIB27">
                     <ce:label>27.</ce:label>
                     <sb:reference>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G</ce:given-name>
                                 <ce:surname>Blum</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Substrate competitive inhibitors of IGF-1 receptor kinase</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biochemistry</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>39</sb:volume-nr>
                              </sb:series>
                              <sb:date>2000</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>15705</sb:first-page>
                              <sb:last-page>15712</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="BIB28">
                     <ce:label>28.</ce:label>
                     <sb:reference>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K</ce:given-name>
                                 <ce:surname>Parang</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Mechanism-based design of a protein kinase inhibitor</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Struct. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:date>2001</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>37</sb:first-page>
                              <sb:last-page>41</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="BIB29">
                     <ce:label>29.</ce:label>
                     <sb:reference>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.J</ce:given-name>
                                 <ce:surname>Harper</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P</ce:given-name>
                                 <ce:surname>LoGrasso</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Inhibitors of the JNK signaling pathway</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Drugs of the Future</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>26</sb:volume-nr>
                              </sb:series>
                              <sb:date>2001</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>957</sb:first-page>
                              <sb:last-page>973</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="BIB30">
                     <ce:label>30.</ce:label>
                     <sb:reference>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.L</ce:given-name>
                                 <ce:surname>Adams</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>p38 MAP kinase: Molecular target for the inhibition of pro-inflammatory cytokines</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Prog. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>38</sb:volume-nr>
                              </sb:series>
                              <sb:date>2001</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1</sb:first-page>
                              <sb:last-page>60</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="BIB31">
                     <ce:label>31.</ce:label>
                     <sb:reference>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.A</ce:given-name>
                                 <ce:surname>Sausville</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Protein kinase antagonists: interim challenges and issues</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Anticancer Drug Des.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>15</sb:volume-nr>
                              </sb:series>
                              <sb:date>2000</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1</sb:first-page>
                              <sb:last-page>3</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="BIB32">
                     <ce:label>32.</ce:label>
                     <sb:reference>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Z</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structural basis of inhibitor selectivity in MAP kinases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Structure</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>6</sb:volume-nr>
                              </sb:series>
                              <sb:date>1998</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1117</sb:first-page>
                              <sb:last-page>1128</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="BIB33">
                     <ce:label>33.</ce:label>
                     <sb:reference>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T</ce:given-name>
                                 <ce:surname>Schindler</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Cell</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>3</sb:volume-nr>
                              </sb:series>
                              <sb:date>1999</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>639</sb:first-page>
                              <sb:last-page>648</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="BIB34">
                     <ce:label>34.</ce:label>
                     <sb:reference>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>X</ce:given-name>
                                 <ce:surname>Zhu</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Structure</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>7</sb:volume-nr>
                              </sb:series>
                              <sb:date>1999</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>651</sb:first-page>
                              <sb:last-page>661</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="BIB35">
                     <ce:label>35.</ce:label>
                     <sb:reference>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structural basis for selective inhibition of Src family kinases by PP1</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chem. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>6</sb:volume-nr>
                              </sb:series>
                              <sb:date>1999</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>671</sb:first-page>
                              <sb:last-page>678</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="BIB36">
                     <ce:label>36.</ce:label>
                     <sb:reference>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G</ce:given-name>
                                 <ce:surname>Brooks</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.B</ce:given-name>
                                 <ce:surname>La Thangue</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The cell cycle and drug discovery: the promise and the hope</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Drug Discov. Today</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>4</sb:volume-nr>
                              </sb:series>
                              <sb:date>1999</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>455</sb:first-page>
                              <sb:last-page>463</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="BIB37">
                     <ce:label>37.</ce:label>
                     <sb:reference>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.R</ce:given-name>
                                 <ce:surname>Webster</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Therapeutic potential of targeting the cell cycle</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chem. Res. Toxicol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>13</sb:volume-nr>
                              </sb:series>
                              <sb:date>1998</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>940</sb:first-page>
                              <sb:last-page>943</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="BIB38">
                     <ce:label>38.</ce:label>
                     <sb:reference>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.M</ce:given-name>
                                 <ce:surname>Senderowicz</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Clin. Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>16</sb:volume-nr>
                              </sb:series>
                              <sb:date>1998</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2899</sb:first-page>
                              <sb:last-page>2986</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="BIB39">
                     <ce:label>39.</ce:label>
                     <sb:reference>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>U</ce:given-name>
                                 <ce:surname>Schulze-Gahmen</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Multiple modes of ligand recognition: crystal structures of cyclin-dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proteins Struct. Funct. Genet.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>22</sb:volume-nr>
                              </sb:series>
                              <sb:date>1995</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>378</sb:first-page>
                              <sb:last-page>391</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="BIB40">
                     <ce:label>40.</ce:label>
                     <sb:reference>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.F</ce:given-name>
                                 <ce:surname>de Azevedo</ce:surname>
                                 <ce:suffix>Jr</ce:suffix>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc. Nat. Acad. Sci. U. S. A.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>93</sb:volume-nr>
                              </sb:series>
                              <sb:date>1996</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2735</sb:first-page>
                              <sb:last-page>2740</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="BIB41">
                     <ce:label>41.</ce:label>
                     <sb:reference>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P</ce:given-name>
                                 <ce:surname>Furet</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structure-based design of potent CDK1 inhibitors derived from olomoucine</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Comput.-Aided Mol. Design</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>14</sb:volume-nr>
                              </sb:series>
                              <sb:date>2000</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>403</sb:first-page>
                              <sb:last-page>409</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="BIB42">
                     <ce:label>42.</ce:label>
                     <sb:reference>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P</ce:given-name>
                                 <ce:surname>Furet</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Identification of cyclin-dependent kinase 1 inhibitors of a new chemical type by structure-based drug design and database searching</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Comput.-Aided Mol. Design</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>15</sb:volume-nr>
                              </sb:series>
                              <sb:date>2001</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>489</sb:first-page>
                              <sb:last-page>495</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="BIB43">
                     <ce:label>43.</ce:label>
                     <sb:reference>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R</ce:given-name>
                                 <ce:surname>Gussio</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structure-based design modifications of the paullone molecular scaffold for cyclin-dependent kinase inhibition</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Anticancer Drug Des.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>15</sb:volume-nr>
                              </sb:series>
                              <sb:date>2000</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>53</sb:first-page>
                              <sb:last-page>66</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="BIB44">
                     <ce:label>44.</ce:label>
                     <sb:reference>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.S</ce:given-name>
                                 <ce:surname>Gray</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Exploiting chemical libraries, structure and genomics in the search for kinase inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Science</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>281</sb:volume-nr>
                              </sb:series>
                              <sb:date>1998</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>533</sb:first-page>
                              <sb:last-page>538</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="BIB45">
                     <ce:label>45.</ce:label>
                     <sb:reference>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S-H</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.O</ce:given-name>
                                 <ce:surname>Lawrence</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structure-based inhibitor design for CDK2, a cell cycle controlling protein kinase</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Pure Appl. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>70</sb:volume-nr>
                              </sb:series>
                              <sb:date>1998</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>555</sb:first-page>
                              <sb:last-page>565</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="BIB46">
                     <ce:label>46.</ce:label>
                     <sb:reference>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M</ce:given-name>
                                 <ce:surname>Ikuta</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Crystallographic approach to identification of cyclin-dependent kinase 4 (CDK4)-specific inhibitors by using CDK4 mimic CDK2 protein</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Biol. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>276</sb:volume-nr>
                              </sb:series>
                              <sb:date>2001</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>27548</sb:first-page>
                              <sb:last-page>27554</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="BIB47">
                     <ce:label>47.</ce:label>
                     <ce:other-ref>
                        <ce:textref>Mendelshon, J. and Baselga, J. (1995) Antibodies to growth factors and receptors. In <ce:italic>Biologic Therapy of Cancer. Principles and Practice</ce:italic>. (DeVita, V.T.J. <ce:italic>et al.</ce:italic> eds), p. 607, J.B. Lippincott</ce:textref>
                     </ce:other-ref>
                  </ce:bib-reference>
                  <ce:bib-reference id="BIB48">
                     <ce:label>48.</ce:label>
                     <sb:reference>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P</ce:given-name>
                                 <ce:surname>Furet</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Modeling study of protein kinase inhibitors:binding mode of staurosporine – origin of the selectivity of CGP52411</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Comput.-Aided Mol. Design</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>9</sb:volume-nr>
                              </sb:series>
                              <sb:date>1995</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>465</sb:first-page>
                              <sb:last-page>471</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="BIB49">
                     <ce:label>49.</ce:label>
                     <sb:reference>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P</ce:given-name>
                                 <ce:surname>Traxler</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P</ce:given-name>
                                 <ce:surname>Furet</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Strategies toward the design of novel and selective protein tyrosine kinase inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Pharmacol. Ther.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>82</sb:volume-nr>
                              </sb:series>
                              <sb:date>1999</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>195</sb:first-page>
                              <sb:last-page>206</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="BIB50">
                     <ce:label>50.</ce:label>
                     <sb:reference>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S</ce:given-name>
                                 <ce:surname>Ghosh</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structure-based design of potent inhibitors of EGF-receptor tyrosine kinase as anti-cancer agents</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Anticancer Drug Des.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>14</sb:volume-nr>
                              </sb:series>
                              <sb:date>1999</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>403</sb:first-page>
                              <sb:last-page>410</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="BIB51">
                     <ce:label>51.</ce:label>
                     <sb:reference>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S</ce:given-name>
                                 <ce:surname>Mahajan</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [α-cyano-β-hydroxy-β-methy-<ce:italic>N</ce:italic>-(2, 5-dibromophenyl)propenamide]</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Biol. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>274</sb:volume-nr>
                              </sb:series>
                              <sb:date>1999</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>9587</sb:first-page>
                              <sb:last-page>9599</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="BIB52">
                     <ce:label>52.</ce:label>
                     <sb:reference>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J</ce:given-name>
                                 <ce:surname>Singh</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structure-based design of a potent, selective and irreversible inhibitor of the catalytic domain of the erbB receptor subfamily of protein tyrosine kinases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>40</sb:volume-nr>
                              </sb:series>
                              <sb:date>1997</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1130</sb:first-page>
                              <sb:last-page>1135</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="BIB53">
                     <ce:label>53.</ce:label>
                     <sb:reference>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.N</ce:given-name>
                                 <ce:surname>Ihle</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The Janus protein tyrosine kinase family and its role in cytokine signaling</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Adv. Immunol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>60</sb:volume-nr>
                              </sb:series>
                              <sb:date>1995</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1</sb:first-page>
                              <sb:last-page>35</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="BIB54">
                     <ce:label>54.</ce:label>
                     <sb:reference>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.A</ce:given-name>
                                 <ce:surname>Witthuhn</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Differential substrate recognition capabilities of Janus family protein tyrosine kinases within the interleukin 2 receptor (IL2R) system: Jak3 as a potential molecular target for treatment of leukemias with a hyperactive Jak–Stat signaling machinery</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Leuk. Lymphoma</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>32</sb:volume-nr>
                              </sb:series>
                              <sb:date>1999</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>289</sb:first-page>
                              <sb:last-page>297</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="BIB55">
                     <ce:label>55.</ce:label>
                     <sb:reference>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.A</ce:given-name>
                                 <ce:surname>Sudbeck</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>5</sb:volume-nr>
                              </sb:series>
                              <sb:date>1999</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1569</sb:first-page>
                              <sb:last-page>1582</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="BIB56">
                     <ce:label>56.</ce:label>
                     <sb:reference>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T</ce:given-name>
                                 <ce:surname>Schindler</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structural mechanism for STI-571 inhibition of abelson tyrosine kinase</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Science</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>289</sb:volume-nr>
                              </sb:series>
                              <sb:date>2000</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1938</sb:first-page>
                              <sb:last-page>1942</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="BIB57">
                     <ce:label>57.</ce:label>
                     <sb:reference>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>U</ce:given-name>
                                 <ce:surname>Kikkawa</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The protein kinase C family: heterogeneity and its implications</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Annu. Rev. Biochem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>58</sb:volume-nr>
                              </sb:series>
                              <sb:date>1989</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>31</sb:first-page>
                              <sb:last-page>44</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="BIB58">
                     <ce:label>58.</ce:label>
                     <sb:reference>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J</ce:given-name>
                                 <ce:surname>Kuriyan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D</ce:given-name>
                                 <ce:surname>Cowburn</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Modular peptide recognition domains in eukaryotic signaling</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Annu. Rev. Biophys. Biomol. Struct.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>26</sb:volume-nr>
                              </sb:series>
                              <sb:date>1997</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>259</sb:first-page>
                              <sb:last-page>288</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="BIB59">
                     <ce:label>59.</ce:label>
                     <sb:reference>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.R</ce:given-name>
                                 <ce:surname>Burke</ce:surname>
                                 <ce:suffix>Jr</ce:suffix>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Phosphoryltyrosyl mimetics in the design of peptide-based signal transduction inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biopolymers</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>60</sb:volume-nr>
                              </sb:series>
                              <sb:date>2001</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>32</sb:first-page>
                              <sb:last-page>44</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="BIB60">
                     <ce:label>60.</ce:label>
                     <sb:reference>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.Z</ce:given-name>
                                 <ce:surname>Qiao</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Rational design, synthesis and biological evaluation of rigid pyrrolidone analogues as potential inhibitors of prostate cancer cell growth</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>11</sb:volume-nr>
                              </sb:series>
                              <sb:date>2001</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>955</sb:first-page>
                              <sb:last-page>959</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="BIB61">
                     <ce:label>61.</ce:label>
                     <sb:reference>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.C</ce:given-name>
                                 <ce:surname>Dalgarno</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>SH3 domains and drug design: Ligands, structure and biological function</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biopolymers</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>43</sb:volume-nr>
                              </sb:series>
                              <sb:date>1997</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>383</sb:first-page>
                              <sb:last-page>400</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="BIB62">
                     <ce:label>62.</ce:label>
                     <sb:reference>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.P</ce:given-name>
                                 <ce:surname>Combs</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Protein structure-based combinatorial chemistry: discovery of non-peptide binding elements to Src SH3 domain</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Am. Chem. Soc.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>118</sb:volume-nr>
                              </sb:series>
                              <sb:date>1996</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>287</sb:first-page>
                              <sb:last-page>288</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="BIB63">
                     <ce:label>63.</ce:label>
                     <sb:reference>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.T</ce:given-name>
                                 <ce:surname>Nguyen</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Exploiting the basis of proline recognition by SH3 and WW domains: design of <ce:italic>N</ce:italic>-substituted inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Science</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>282</sb:volume-nr>
                              </sb:series>
                              <sb:date>1998</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2088</sb:first-page>
                              <sb:last-page>2092</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="BIB64">
                     <ce:label>64.</ce:label>
                     <sb:reference>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.K</ce:given-name>
                                 <ce:surname>Sawyer</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Src homology-2 domains: structure, mechanisms and drug discovery</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biopolymers</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>47</sb:volume-nr>
                              </sb:series>
                              <sb:date>1998</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>243</sb:first-page>
                              <sb:last-page>261</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="BIB65">
                     <ce:label>65.</ce:label>
                     <sb:reference>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.L</ce:given-name>
                                 <ce:surname>Lunney</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structure-based design of a novel series of nonpeptide ligands that bind to the pp60src SH2 domain</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Am. Chem. Soc.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>119</sb:volume-nr>
                              </sb:series>
                              <sb:date>1997</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>12471</sb:first-page>
                              <sb:last-page>12476</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="BIB66">
                     <ce:label>66.</ce:label>
                     <sb:reference>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.L</ce:given-name>
                                 <ce:surname>Buchanan</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structure-based design and synthesis of a novel class of SRC SH2 inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>19</sb:volume-nr>
                              </sb:series>
                              <sb:date>1999</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2353</sb:first-page>
                              <sb:last-page>2358</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="BIB67">
                     <ce:label>67.</ce:label>
                     <sb:reference>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.C</ce:given-name>
                                 <ce:surname>Shakespeare</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structure-based design of novel bicyclic nonpeptide inhibitors for the Src SH2 domain</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>43</sb:volume-nr>
                              </sb:series>
                              <sb:date>2000</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3815</sb:first-page>
                              <sb:last-page>3819</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="BIB68">
                     <ce:label>68.</ce:label>
                     <sb:reference>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W</ce:given-name>
                                 <ce:surname>Shakespeare</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structure-based design of an osteoclast-selective, nonpeptide Src homology 2 inhibitor with in vivo antiresorptive activity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc. Nat. Acad. Sci. U. S. A.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>97</sb:volume-nr>
                              </sb:series>
                              <sb:date>2000</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>9373</sb:first-page>
                              <sb:last-page>9378</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="BIB69">
                     <ce:label>69.</ce:label>
                     <sb:reference>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P</ce:given-name>
                                 <ce:surname>Furet</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structure-based design and synthesis of high affinity tripeptide ligands of the Grb2-SH2 domain</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>41</sb:volume-nr>
                              </sb:series>
                              <sb:date>1998</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3442</sb:first-page>
                              <sb:last-page>3449</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="BIB70">
                     <ce:label>70.</ce:label>
                     <sb:reference>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P</ce:given-name>
                                 <ce:surname>Furet</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structure-based design, synthesis, and X-ray crystallography of a high-affinity antagonist of the Grb2-SH2 domain containing an asparagine mimetic</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>42</sb:volume-nr>
                              </sb:series>
                              <sb:date>1999</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2358</sb:first-page>
                              <sb:last-page>2363</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="BIB71">
                     <ce:label>71.</ce:label>
                     <sb:reference>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.A</ce:given-name>
                                 <ce:surname>O'Brian</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Protein kinase Cα: a novel target for the therapy of androgen-independent prostate cancer?</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncol. Rep.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>5</sb:volume-nr>
                              </sb:series>
                              <sb:date>1998</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>305</sb:first-page>
                              <sb:last-page>309</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="BIB72">
                     <ce:label>72.</ce:label>
                     <sb:reference>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Crystal structure of the cys2 activator-binding domain of protein kinase C δ in complex with phorbol ester</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>81</sb:volume-nr>
                              </sb:series>
                              <sb:date>1995</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>917</sb:first-page>
                              <sb:last-page>924</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
               </ce:bibliography-sec>
            </ce:bibliography>
         </tail>
      </converted-article>
   </xocs:serial-item></xocs:doc></originaltext></full-text-retrieval-response>